In Australia, while the prevalence of smoking is declining in the overall community, it remains higher among people with mental illness.1 Compared to both the overall population and to people without mental illness, people with recent mental illness have higher smoking rates, higher levels of nicotine dependence, and a disproportionate health and financial burden from smoking.2,3
Mental health problems are common within the Australian population: in 2022–23, 18% of Australians aged 18+ reported that they had been diagnosed with and/or treated for one or more mental illnesses in the past year.4 More than two in five (43%) Australians aged 16–85 report having experienced a mental disorder at some time in their life.5
People with mental illness have a substantially higher prevalence of smoking and those who smoke tend to smoke more heavily than the overall population.6 Data from the 2022–23 National Drug Strategy Household Survey showed that Australian adults who reported having been diagnosed or treated for mental illness in the past year were about twice as likely to currently smoke than those who had not been diagnosed or treated in the past year—see Figure 9A.3.1.7 People who smoked daily were about twice as likely to have high/very high levels of psychological distress compared with people who had never smoked (29% and 15%, respectively) and were twice as likely to have been diagnosed or treated for a mental health condition (31% and 15%).4
Smoking prevalence tends to increase alongside the severity of the psychiatric disorder.8 For example, two Australian studies conducted 10 years apart both found that among people living with psychotic disorders, about 70% of men and 60% of women smoked.1,9 Results from the 2022 National Health Survey10 show a similarly high prevalence of smoking among people with mental disorders, and also show the extremely high prevalence of smoking among those with harmful use or dependence on drugs and those with schizophrenia—see Figure 9A.3.2.
Similarly, smoking—especially daily smoking—is much more common among adults who meet the criteria for alcohol dependence, or who report drinking in ways that could be harmful or hazardous. In 2019, compared with those at low risk, adults who reported drinking alcohol at harmful or hazardous levels were more than twice as likely to report smoking daily, while those who met the criteria for alcohol dependence were more than three times as likely to smoke daily—see Figure 9A.3.3.13
International data also show high smoking rates among those with mental illness. Research in the US14 and the UK15 has found large disparities between smoking in the overall population and among people with mental illness.
About one in five Australian secondary school students report that they have a mental health condition.12 Limited data suggest that smoking appears highly prevalent among young people with diagnoses of mental illness.16,17 An Australian study of young people (aged 12–25) presenting to a youth mental health service between 2016 and 2018 found that 23.4% were regular tobacco users. Daily tobacco use was more prevalent among young adults (18–25-year-olds) compared to adolescents (12–17-year-olds; 23.1% vs. 7.2%).18 Another Australian study in 2017 found that among young people aged 15–25 attending youth mental health services, 29% had smoked in the past week.19 An earlier Australian study found that in 2013, among young people presenting for primary mental healthcare, 23% of 12–17 year olds, 36% of 18–19 year olds, and 41% of 20–30 year olds reported daily smoking.20
People with mental illness who smoke also report high levels of consumption. US studies21,22 have estimated that while nicotine-dependent individuals with a comorbid psychiatric disorder make up only 7.1% of the population, they consume more than one-third of all cigarettes. Australian research found that in 2019, people who regularly smoked with mental illness smoked an average of about one extra pack per week compared to those without mental illness (117 and 98 cigarettes per week, respectively).6 Among people who smoke with severe mental illness, other studies indicate average daily consumption of 30 cigarettes, with a range of 5–80 per day.23,24
While the prevalence of smoking has declined over time in the overall community, it remains high among people with mental illness.1 For example, the prevalence of smoking among Australians with psychotic disorders remained steady at about 67% between 1997 and 2010, while smoking in the total Australian population declined from 26% to 19%.1 Similarly in the US, several studies have shown growing disparities over time between smoking in the overall population and among people with high levels of psychological distress and serious mental illness.25-28 As overall smoking rates decline, those with mental illness comprise a greater proportion of the remaining people who smoke—see Figure 9A.3.4.29 These findings suggest that tobacco control policies and cessation interventions that have effectively reduced smoking in the overall population may not have been as effective for people with mental illness.
Nonetheless, there are some encouraging trends. Several US studies have shown reductions in smoking prevalence and increased quit rates over time among people with psychological distress and some mental disorders.30-32 Australian research has found that there was a significant decrease in regular smoking—see Figure 9A.3.5—and significant increases in never smoking and in the proportion of people that had ever smoked who had quit among people with mental illness between 2004 and 2019.6
Data from the ABS National Health Surveys similarly suggest some declines in daily smoking prevalence among those with mental illness and substance use problems10,33-36—see Figure 9A.3.6.
In 2024, mental and substance use disorders were the second leading cause of Australia’s disease burden, behind cancer.37 High smoking rates among people with mental illness contribute to higher levels of tobacco-caused morbidity and mortality.38 Compared with the overall population, people with mental illness have a disproportionate health and financial burden from smoking.2,3 Australian men with mental illness live 15.9 years less and women live 12 years less than those without mental illness,39 and most of the excess morbidity and mortality is attributable to smoking-related illnesses such as cardiovascular disease, respiratory disease, diabetes, and cancer.39-41 The gap in life expectancy between those with and without mental illness has also widened over time, largely due to smoking-related diseases.39 People with mental illness who smoke are far more likely to die from their smoking than as a result of their psychiatric condition.2,39 One study found that among people with serious mental illness, those who smoked had a reduced life expectancy of 5–7 years compared with non-smokers.42
Research in the US estimated that from 2018 to 2060, approximately 484,000 smoking-attributable deaths will occur among adults with depression, but up to 264,000 of those deaths could be avoided with comprehensive tobacco control strategies.43 Another modelling study estimated that widespread uptake of any cessation treatment (behavioural counselling, pharmacological, or combination) among patients with depression in the US would avert 32,000 deaths and result in 138,000 life-years gained by 2100.44
People with mental illness and mental health workers often perceive smoking to be helpful in relieving or managing psychiatric symptoms.8,45 However, recent evidence suggests that the reverse is true; people who quit smoking may experience improvements in their mental health and quality of life.45-48 People with mental illness who quit smoking report lower levels of psychological distress6 and mental health symptoms49,50 than those who continue to smoke. Quitting smoking has a similar sized effect to taking anti-depressants on improving mental health.51
As well as contributing to poorer health outcomes, smoking can also exacerbate financial stress among people with mental illness. Research in the UK estimated that smoking pushes an estimated 130,000 people with a common mental disorder into poverty per year.52 In the US, one study found that people with depression who smoke were more likely than those without depression to experience financial distress and smoking-induced deprivation, with about one-third of people who smoke with depression foregoing essentials to pay for tobacco.53 In Australia in 2000, it was estimated that people with a psychotic illness who smoked and were in receipt of a disability support pension spent more than one-third of their pension on tobacco products. Smoking plays an important role in the cycle of poverty and disadvantage experienced by people with mental illness.54
The mechanisms underlying the relationship between mental health conditions and smoking are complex, and vary between disorders.55 There are a number of potential explanations for why people with mental health problems are more likely to smoke; risk factors for smoking among the overall population are experienced to a greater degree, and there are also unique factors that contribute to the higher prevalence of smoking. These include:
The self-medication hypothesis suggests that people with mental illness smoke to ease the symptoms of depression, schizophrenia, substance abuse and other disorders, and is the most common explanation for the very high prevalence of smoking among this group.57,74 The hypothesis has also been expanded to suggest that smoking can relieve side effects of antipsychotic medication.60 People who smoke with mental illness frequently cite stress and anxiety relief as reasons for smoking,64 and many erroneously believe that smoking is helpful for relaxation.16,19 However, results from recent studies have not supported the self-medication hypothesis75,76 (with the exception of ADHD—see Section 9A.3.5.4). The supposed beneficial effects of smoking on stress can be largely attributed to the temporary alleviation of nicotine withdrawal symptoms, which creates the false impression that smoking is relaxing.77 However, smoking actually increases stress levels overall.8 Several studies have shown that quitting smoking is associated with reduced depression, anxiety, and stress and improved positive mood and quality of life compared with continuing to smoke among people with psychiatric disorders.45,46
A 2015 review of smoking among people with schizophrenia concluded that, despite some enhanced performance for cognitive tasks, smoking appears to be less beneficial on schizophrenic symptomology than generally assumed, while clearly increasing the risk of cancer and other smoking-related diseases responsible for early mortality.75 Another similarly highlights the lack of evidence for favourable effects on symptoms, but substantially increased health risks among smokers with schizophrenia.69 Two more recent meta-analyses found strong evidence that smoking is in fact associated with cognitive impairment among people with schizophrenia.78,79 Another found evidence for more severe positive symptoms but less severe extrapyramidal side effects (e.g., involuntary muscle contraction, tremors) among people with schizophrenia who smoke compared with those who do not.80 A 2015 systematic review and meta-analysis concluded that daily tobacco use is associated with increased risk of psychosis and an earlier age at onset of psychotic illness. The authors propose that smoking could have a causal role in psychosis, which further brings into question the self-medication hypothesis.81 Additional systematic reviews and meta-analyses suggest that smoking, and prenatal smoke exposure, may be an independent risk factor for schizophrenia.82,83 Smoking may also increase the risk of other mental illnesses,84 including anxiety, depression,8,73,83,85-87 and bipolar disorder.73,83,88
Another proposed explanation for the higher rates of smoking among people with mental health problems is that they do not want to quit or try to quit. However, Australian and international research has shown that smokers with mental illness are just as likely to attempt to quit and more likely to use cessation support. Nonetheless, they appear to experience less success maintaining cessation than people without mental illness.6,15,89 Although treating tobacco dependence in people with mental illness is challenging, several randomised treatment trials and systematic reviews have documented that success is possible.90 People with mental illness who smoke are able to quit with standard cessation approaches with minimal effects on psychiatric symptoms.91
Socio-economic status (SES) is inversely related to smoking, such that the prevalence of smoking is substantially higher among lower socio-economic groups. Mental disorders are associated with low incomes and higher levels of debt;92 thus, there is likely interplay between low socioeconomic status, mental illness, and smoking. In 2011–12, 62% of working age Australians with a mental illness were employed, compared to 80% of those without a mental illness.93 One study found that people with mental illness who smoke frequently smoke to combat boredom, and suggested that the higher rates of unemployment among this group may contribute to more frequent experiences of boredom and therefore smoking.64
Looking at why and how some people resist smoking despite being at-risk can also shed light on potential protective factors.94 One small study with people diagnosed with mental illness found that strong, negative attitudes to smoking as children that have persisted into adulthood, lasting associations with smoking, a clear sense of ‘self’ separate from peers from an early age, and developing a range of coping strategies and external supports not related to smoking served as protective factors from taking up smoking.94
People with mental health problems face a number of unique barriers to quitting, including misperceptions regarding the safety of stopping smoking, higher levels of nicotine dependence and withdrawal, lower degree of participation in programs, misperceptions of low motivation to quit, socio-economic factors, and systematic barriers to quitting in mental healthcare settings. A systematic review identified smoking for stress management, lack of support from health and other service providers, the high prevalence and acceptability of smoking in vulnerable communities, and the maintenance of mental health as perceived barriers among those with mental illness.95 An Australian study of smoking behaviours among institutionalised psychiatric populations found systematic barriers to quitting, including cigarettes being the currency by which economic, social and political exchange took place and complex processes of reinforcement to smoke. Escape from the smoking culture of the settings appeared to be extremely difficult for clients and staff.96
There is a common misperception within mental health settings that quitting smoking interferes with recovery from mental illness, eliminates a coping strategy, and leads to decompensation in mental health functioning.90 People with mental illness also report similar concerns, which can hinder quit attempts.97 However, several major reviews have found that quitting does not lead to deterioration in symptoms of schizophrenia, depression, or severe mental illness,98,99 and is in fact associated with improvements in mental health among people with psychiatric disorders.45,46 Smoking cessation also does not exacerbate anxiety or PTSD symptoms, or lead to psychiatric hospitalisation or increased use of alcohol or illicit drugs.58,100 Indeed, smoking cessation interventions during addiction treatment appear to enhance rather than compromise long-term sobriety.101 Two studies examining whether the treatment of ADHD can enhance response to smoking cessation intervention found no association overall between abstinence and change in ADHD symptoms,102,103 and another found that quitting can reduce anxiety and depressed mood in smokers with ADHD.104 Quitting is also associated with a decreased likelihood of suicide attempt.105 Lifetime history of major depression does not appear to be an independent risk factor for failure in smoking cessation treatment.106
Another common misperception is that people with mental illness do not want to quit, which can lead to a lack of encouragement and support to do so.107 A review of smoking cessation in inpatient psychiatry settings found that it is rare or often delayed.108 A study of mental health centres found that the most common barrier to staff implementing smoking cessation treatment was a perceived lack of patient interest in quitting.109 Although the co-presence of mental illness can make quit attempts more challenging110 and less successful,111 people with mental disorders who smoke are motivated to quit.6,112 Studies involving patients recruited from outpatient and inpatient psychiatric settings suggest that they are just as likely as the overall population to want to quit smoking.58
Further, contrary to common beliefs, greater psychiatric symptoms have been shown to predict greater, not lesser, motivation to quit smoking.113 In British surveys, about half of those with mental illness who smoke have expressed an interest in quitting when asked.114 In the US, 20–25% of people with mental illness who smoke report that they intend to quit smoking in the next 30 days, and another 40% say they intend to do so in the next six months.90 Another population-level study in the US found that smokers with mental illness were more likely than those without mental illness to attempt quitting, and just as likely to use cessation treatment.115 Inpatients with mental health disorders appear to be no less motivated to stop smoking than those without mental health disorders and their use of NRT during hospitalisation is similar.116 One Victorian study of consumers at a psychiatric disability rehabilitation and support service found that while smoking rates were almost four times higher than the total population, there was high interest in quitting and cutting down.117 US research found that, among a sample of women with PTSD symptomatology and serious mental illness, readiness and intention to quit smoking was high.118 People with mental illness who smoke cite similar reasons for wanting to quit as the overall population. For example, one study found that health concerns (73%), cost (71%), advice from a doctor (54%), and advice from others (64%) prompted a desire to quit, while social support from family and friends (58%), direction from a doctor (46%), use of NRT (31%), and the advice of friend who had quit (23%) were factors that enabled quitting.119
Smoking has a disproportionate impact on the mental and physical health of people with mental illness, therefore treating nicotine dependence should be a high priority and form part of routine care.8 However, progress in the development of cessation treatments for people with mental health problems has traditionally been slow, in part because people with a current mental disorder have been excluded from most smoking cessation trials.120,121 Given the evidence showing that quitting is typically not detrimental to psychiatric symptoms and, in fact, appears to improve mental health and wellbeing,45,46,122 cessation should be encouraged and supported among people who smoke with comorbid mental disorders.55 However, as with any other stressor, the stress of cessation could temporarily affect symptoms;47,58 therefore, monitoring of patients’ psychiatric status during the quitting process is warranted.55,123 Nonetheless, people with a mental illness should be offered the same smoking cessation interventions that have been shown to be effective in the overall population,123,124 with optimal treatment comprising a combination of behavioural counselling and NRT/pharmacotherapy.125,126 People who smoke with chronic mental illness can successfully quit with standard cessation approaches, and longer maintenance on pharmacotherapy can reduce the typically high rates of relapse without detrimental effects on psychiatric symptoms.91 People who smoke with mental illness are as motivated to quit as those without mental illness,6 and despite lower overall success rates, can quit successfully.112 Further, unsuccessful quit attempts do not appear to worsen mental health symptoms, which should reassure healthcare providers who may be hesitant to encourage cessation.127 Integrating brief tobacco cessation interventions such as the ‘5As’ (ask, assess, advise, assist, arrange follow-up) into routine mental health treatment, and providing more intensive intervention when required, forms an important part of reducing the large health disparities between those with and without a mental health problem.8,55,128,129
An important consideration in treating nicotine dependence is the impact of smoking on psychiatric treatment. Smoking complicates the treatment and course of psychiatric disorders through its profound effect on the metabolism of pharmacotherapies, and is therefore one of the factors that leads to individual differences in drug responses.55 For example, smoking can interfere with the medications taken for schizophrenia and depression, therefore the doses of some psychotropic medications may need to be decreased following cessation.124,130 Patients with mental illness can be offered the same cessation medications as the overall population,131 but should be monitored closely. The typically higher levels of nicotine dependence among smokers with mental illness mean that larger doses of NRT, combination pharmacotherapy, and a longer duration of therapy may be necessary.8 Several Australian studies have supported the potential or effectiveness of integrated cessation interventions in community mental health settings.132-135 Integrating cessation into mental healthcare can increase screening for smoking and the provision and uptake of cessation advice and support136-138 and can successfully increase quit rates.139 Australian research has also found that cessation support after discharge from an inpatient psychiatric facility was effective in encouraging quit attempts and reducing cigarette consumption up to 6 months post-discharge.140
In Australia, Quitline is the most accessible behavioural intervention, and research has shown that such services can have positive impacts on smoking cessation among people with mental illness141 and are just as effective as face-to-face interventions.142 Many quitline services offer coordinated care with clinicians, and some have introduced monitoring of nicotine withdrawal symptoms and common medication side-effects for people with mental illness.143 However, although use of quitlines is more common among people with mental illness in Australia than among those without, they are underutilised.6 Interviews with Australians with mental illness who smoke revealed that many held negative perceptions about the usefulness of Quitline, highlighting that strategies may be needed that raise awareness about the service.144 Other Australian research has shown that targeted videos providing smoking cessation information and advice to people with mental illness who smoke can be well-received and increase knowledge about quitting.145
Compared to people without depression, people with depression are about twice as likely to smoke, and are less likely to succeed in quit attempts.146,147 People who smoke also have significantly higher rates of lifetime depression.55 Compared to those without depression, people who smoke with depression are more nicotine dependent, more likely to suffer from negative mood changes after nicotine withdrawal, more likely to relapse, and experience disproportionate morbidity and mortality from smoking-related disease.146 Evidence suggests that major depression may be a risk factor for progression of nicotine dependence.148 Depression is also related to psychosocial characteristics that make it more difficult to stop smoking, for example, lower self-esteem and self-efficacy for quitting, and greater likelihood of unemployment, poorer social support networks and poorer physical health.149
Findings from the Four Country (Canada, US, UK, and Australia) International Tobacco Control Study showed that people who smoke with depressive symptoms or diagnosis are motivated to quit and make more quit attempts than people without depression, and150,151 a meta-analysis suggests that a lifetime history of major depressive disorder does not predict failure to quit smoking.106 A 2015 review of depression and smoking concluded that: people with depression who smoke are motivated to quit; smoking cessation does not exacerbate symptoms of depression; depression does not have a negative impact on smoking cessation outcomes; and the self-medication hypothesis does not account for tobacco dependence and depression co-morbidity.152 Indeed, a growing body of evidence supports the causal role of smoking in the development of depression153 and the beneficial role of quitting in reducing depression.45,154
Smoking cessation interventions, particularly pharmacological treatments, appear to increase short-term and long-term smoking abstinence in individuals with current depression.154,155 A 2013 Cochrane review concluded that adding a psychosocial mood management component to a standard smoking cessation intervention increases long-term cessation rates in smokers with both current and past depression when compared with the standard intervention alone.146 Several RCTs have supported the safety and effectiveness of varenicline in promoting cessation among people with depression,156 which appears to be superior to NRT and bupropion for this group.157,158-160 Contingency management (i.e. incentives/rewards for quitting) may also be a promising strategy for reducing smoking among people with depressive symptomology.161
A review also notes that there appears to be a reduction in the concentration of serum levels of common anti-depressants (fluvoxamine, duloxetine, trazodone and mirtazapine) in people who smoke, which likely necessitates careful choice and adaptation of medications based on smoking and smoking cessation.130
Among people with anxiety disorders, smoking rates appear to range from 31.5% for people with social phobia to 54.6% for people with generalised anxiety disorder.162 Obsessive-compulsive symptoms are also associated with tobacco use, dependence severity and greater withdrawal symptoms during quit attempts.163,164 Despite the high rates of smoking among those with anxiety disorders, and evidence showing that they are motivated to quit,165 there is a dearth of evidence regarding effective cessation interventions for this population.55 A randomised controlled trial published in 2011 found that anxiety diagnoses were common among treatment-seeking smokers and were related to increased motivation to smoke, elevated withdrawal, lack of response to pharmacotherapy, and impaired ability to quit smoking.166 Another study found that people with social anxiety disorder who smoke experienced higher levels of craving and urge to smoke during quit attempts, which could explain their worse cessation outcomes. Such people would likely benefit from additional treatment aimed at managing or reducing their social anxiety symptoms, and NRT also seemed to help alleviate the relationship between social anxiety and cravings.167
A subgroup analysis of a large randomised controlled trial examining the effectiveness of pharmacotherapies for smoking cessation in people with anxiety disorders found that they were more likely than those without psychiatric illness to experience neuropsychiatric adverse events during quit attempts, regardless of treatment. Nonetheless, findings supported the use of varenicline for cessation in those with generalised anxiety disorder and panic disorder, and the use of NRT for those with panic disorder.168 Another paper from the same trial reported that varenicline, bupropion, and nicotine patch are well tolerated and effective in adults with anxiety disorders. Varenicline showed greater effectiveness than bupropion, NRT, and placebo, and combination bupropion and NRT was more effective than placebo.158
Smoking is associated with suicidal ideation, suicide plan, suicide attempt, and suicide death,169,170 but this association is reduced when a person quits.105 Among people with psychosis, one study estimated that smoking contributed to 21% of suicidal behaviours;171 reducing consumption may also reduce suicidality in this population.171 Smoking is also associated with suicide attempts among people with bipolar disorder.172 A recent systematic review and meta-analysis found that among people with psychosis and bipolar disorder, those who smoke have 1.7 the odds of having reported a suicide attempt compared to non-smokers.173 Researchers have suggested that smoking should be routinely screened for among people with suicidal ideation.170,174
ADHD is one of the most common psychiatric disorders, and is associated with a wide range of impairments and risks into adulthood.175 Smoking is one such risk, with young people with ADHD beginning smoking earlier, and being two to three times more likely to smoke, compared to those without ADHD. The substantially higher prevalence of smoking persists into adulthood, and adults with ADHD are also less likely to be successful at quitting.176-178 The risk of smoking also increases with the severity of symptoms.179,180
There is a growing body of evidence that stimulant medication, which is a front-line treatment of ADHD, may influence smoking-related outcomes.176 Nicotine and stimulant medications operate on the same pathways in the brain, and both appear to help alleviate some of the symptoms of ADHD, which may help explain the very high rates of smoking among this group.181 Research has shown that nicotine is experienced as more pleasurable as reinforcing among young people with ADHD.182 ADHD medication (i.e., stimulant treatment) reduces smoking rates and smoking withdrawal, therefore early and consistent stimulant treatment of ADHD may reduce smoking risk.176,183-185 Bupropion, NRT, and possibly varenicline—approved smoking cessation medications—have also shown efficacy in treating symptoms of ADHD;183,186 however, further research is needed to examine its effectiveness in treating comorbid ADHD-smoking.55 One RCT found that varenicline reduced smoking and withdrawal in smokers with ADHD with high, but not low, hyperactivity/impulsivity symptoms.187 Another RCT found that inattention symptoms were associated with poorer cessation outcomes among adolescents with ADHD who were treated with varenicline for smoking.188 Non-pharmacological interventions, particularly cognitive-behavioural therapy, also show promise for the treatment of ADHD, and warrant further investigation for supporting cessation among this population.55 Limited evidence also suggests that financial incentives may be a useful approach for promoting short-term cessation in adults with ADHD who smoke.189
Smoking prevalence among people with substance use disorders is substantially higher than the overall population.11,21,31,190-197 People with substance or alcohol use disorders also have greater nicotine dependence, lower quitting, and differences in quit attempts and withdrawal symptoms compared with people without such disorders.198 Many people who successfully overcome their substance use disorder will go on to die from a smoking-related disease.199 An Australian study examining alcohol misuse among people who smoke found that they were 3.8-fold more likely to have a higher level of alcohol consumption than non-smokers.200 Many health risks for dual use of alcohol and tobacco are multiplicative rather than simply additive. For example, the risk of oesophageal cancer is greater among heavy alcohol users as a result of alcohol allowing tobacco toxins to penetrate more deeply to basal layers.201 Similarly, there is evidence that smoking cannabis is a risk factor for many of the same illnesses as tobacco.202-204 Cannabis poses unique problems for users since it is often mixed with tobacco, potentially inducing double dependence. In 2022–23, 33% of Australians who smoke reported recent use of cannabis, compared to 9% of non-smokers.7
Treatment centres for substance use disorders have traditionally not prioritised treating nicotine addiction due to lack of staff training, lack of integration into usual care, and because of the common misperception that quitting may be detrimental to the treatment of alcohol or other drug use.205-207 Substance abuse counsellors often have limited knowledge of the smoking cessation medications available for those trying to quit208 and their implementation of tobacco cessation guidelines is inconsistent.209 A study of staff and management attitudes and practices in Australia found smoking received little systematic attention, with concerns about possible negative impact on other treatments, absence of policy, and lack of training being major impediments.210 Research in the US found that people with a substance use disorder who smoke who had undergone addiction treatment were less likely to quit smoking than those who had never received such treatment, possibly due to false beliefs about smoking as a coping strategy and staff attitudes that may discourage cessation.211 Some centres may even endorse occasional smoking by staff with clients212 or rely on cigarettes to stabilise mood in their patients.58,213
Contrary to staff perceptions, people with substance use disorders who smoke are motivated to quit.214 However, despite this motivation to quit, there appears to be a wide variation in readiness to seek help to do so,58,101,213,215 which may be due to a lack of confidence in or wariness of quitting multiple substances at once.215 Research in the US showed that when provided with a tobacco free treatment environment, patients with substance abuse and mental illness can and do make the decision to quit tobacco and maintain their abstinence, which in turn helps them to remain sober.216 While negative affect can hinder quit attempts, patients in an addictions treatment setting can successfully quit smoking regardless of current depressive symptoms.217 In the US, despite being lower than for people without the disorders, the smoking quit rates for people with alcohol use disorders has increased over time.31
Perhaps most importantly, smoking interventions and cessation during substance use treatment appear to enhance rather than compromise long-term abstinence from other addictive drugs.112,218-221 Including cessation interventions in the course of addiction treatment can reduce consumption,222 increase the provision of advice to quit,223 increase use of cessation aids,192,222,224 and increase quit attempts among people who smoke.225,226 A 2015 systematic review of smoking cessation interventions for adults in substance abuse treatment or recovery concluded that NRT, behavioural support, and combination approaches appear to increase smoking abstinence in those treated for substance use disorders.227 Some research indicates that drug treatment clients can successfully quit smoking at rates similar to the overall population when given access to an intensive intervention.228 Several studies suggest that varenicline may promote smoking changes229 and concurrently help reduce heavy drinking in people with alcohol use disorders.230-233 However, use of bupropion by abstinent alcoholic smokers does not appear to increase long-term smoking cessation.234 A 2021 meta-analysis concluded that varenicline may promote smoking cessation in people with alcohol dependence, but there was no clear evidence for the use of naltrexone, topiramate or bupropion.235 For methadone maintenance patients, varenicline,236 NRT,237 or combinations of NRT and behavioural support238 may be effective for reducing tobacco use. For co-users of tobacco and cannabis, evidence suggests that treating both simultaneously is a promising strategy.239
Several studies have explored the role of contingency management (i.e., financial incentives) in promoting abstinence. One study found that contingency management was associated with more short-term abstinence and lowered nicotine addiction among current and former injecting drug users.240 Several studies have supported the use of contingency management when combined with pharmacotherapies and/or behavioural counselling.241-243 Contingency management may also promote smoking reduction in more severe substance abusers, such as those in residential services and opioid-maintained patients,244-246 and also among pregnant women with substance use disorders.247 Such interventions appear to increase abstinence self-efficacy among residential substance abuse treatment patients.248 Increasing tolerance for withdrawal and abstinence discomfort, addressing expectations, and increasing motivation may also be important when implementing incentive programs.249 Other strategies include brief advice plus NRT, which appears to be a cost-effective way to reduce smoking in residential alcohol treatment,250 and an Australian study found that a group program showed promise for reducing smoking among people attending residential alcohol and other substance dependence treatment.251 Digital interventions252 and quitlines253 may also be helpful for addressing co-use of tobacco and other drugs.
As with mental health and correction services, public health experts have identified a need for policy and training initiatives to address past neglect of tobacco control issues.254,255 Systematic intervention around the 5As framework, tailored to the needs of client groups, would provide a good foundation for this work. Factors promoting smoking cessation programs within substance abuse treatment settings include supportive systems and integration within other treatments,138 educating providers about the beneficial effects of cessation for their clients, staff training, and encouraging and assisting staff to quit.213 One study found that an intervention based on organisational change helped to shift the treatment system culture and increase tobacco services in a residential addiction treatment setting.255 Policies that mandate smoking cessation interventions as part of substance use disorder treatment can increase adoption and implementation.256
Future clinical research in this area and its translation into practice may be improved by recruiting and retaining a broader range of people with drug dependencies, particularly those who are not currently being reached through mainstream interventions, and by longer-term follow-up.257 Research as to the role of social bonding around tobacco use and its normalisation in drug treatment settings may be useful in guiding future practice.215
The prevalence of current smoking in individuals with PTSD is substantially greater than that for the overall population.258-261 A systematic review found that people who smoke were about twice as likely to have PTSD than non-smokers in the overall population, and more than one-third of people with PTSD smoked daily.258 Another review concluded that there appears to be a causal relationship between PTSD and smoking that may be bidirectional. PTSD, rather than trauma exposure itself, appears to have a greater influence on a person’s risk of smoking, and specific PTSD symptoms may contribute to smoking and disrupt cessation attempts.262 Evidence suggests that people with PTSD smoke to cope with negative affect and anxiety,91,258,259,261 and PTSD is associated with higher levels of consumption (i.e., more cigarettes smoked per day).263 Nonetheless, evidence suggests that PTSD is associated with more overall quit attempts (albeit with less success), and there has been a decline in smoking among people with PTSD over time.258
To date, there have been a small number of studies examining smoking cessation interventions in smokers with PTSD. Given their greater difficulty maintaining quit attempts, people with PTSD may benefit from more intensive and targeted interventions,259 and from proactive outreach to initiate treatment.264 A systematic review published in 2018 examined integrated, specialised treatments for comorbid smoking—PTSD, including preliminary treatment studies and RCTs in both veteran and general clinical samples. It concluded that mobile technology shows promise for providing effective, lower cost, and wide-reaching PTSD—smoking intervention. There is also evidence to support the integration of smoking cessations aids (e.g., varenicline) and smoking cessation counselling into existing PTSD treatments (i.e., prolonged exposure), particularly for people experiencing elevated PTSD symptom severity.258
Severe mental illness, or serious mental illness (SMI), are umbrella terms that generally refer to diagnoses of bipolar disorder or schizophrenia. People with SMI generally have very high rates of nicotine dependence and smoking—between 40% and 80%—and people with SMI who smoke have poorer mental and physical health outcomes than those who do not smoke.265 Nonetheless, evidence suggests that people with SMI who smoke are motivated to quit and often seek help for quitting.266 A systematic review published in 2021 of cessation interventions for people with SMI concluded that it is currently unclear which interventions are most effective. However, it identified common evidenced-based components across studies that supported smoking cessation and/or reduction, including cessation medications (e.g., NRT, bupropion), motivational enhancement techniques, and cessation education and skills training.265 A meta-analysis of RCTs published in 2019 concluded that varenicline is effective at 3- and 6-months for people with SMI. While bupropion and NRT showed short-term effectiveness, this was not sustained.267 The largest RCT to date examining cessation interventions for people with SMI concluded that a tailored combined pharmacological and behavioural approach was effective in supporting short- and long-term quitting.268,269
Another review supported the effectiveness of tailored person-based smoking cessation interventions for people with SMI.270 An Australian RCT found that telephone-delivered smoking cessation support led to significant reductions in cardiovascular disease risk and smoking across 36 months among people with psychotic disorders.271 Although a number of guidelines have been developed for smoking cessation in people with severe mental illness, a review found that they varied considerably in quality, and many did not adequately describe their methods or report conflicts of interest.272
People with bipolar disorder are about three and a half times more likely to smoke than the overall population, and have much lower quit rates than smokers without a comorbid condition.273,274 Research has consistently found that the prevalence of smoking is approximately two to three times higher among people with bipolar disorder than in the overall population.55,275 In addition to contributing to increased morbidity and mortality, smoking has also been implicated in the progression of bipolar disorder.276 However, despite these high rates of comorbidity and related morbidity, there is only a modest field of research focusing on smoking among individuals with bipolar disorder.277 To date, there have only been a small number of clinical studies on cessation interventions among smokers with bipolar disorder. Researchers have highlighted challenges in recruitment and low eligibility rates as significant hurdles to such studies, and have noted that many health professionals remain wary of encouraging cessation among people with bipolar disorder.274 Nonetheless, recent research has attempted to address this gap.
Schizophrenia is a chronic and severe mental illness that affects about one in 100 people.285 A meta-analysis of studies from 20 different countries found that people with schizophrenia have more than five times the odds of current smoking than the overall population.286 People with schizophrenia smoke more heavily and are more nicotine dependent,287 and extract more nicotine from each cigarette.288 Tobacco-related conditions are responsible for about half of total deaths in people with schizophrenia.289 Despite wanting to quit,290 a meta-analysis found that the prevalence of smoking cessation was 15% in schizophrenia patients, compared with 23% in healthy controls.291 These lower success rates are partly because of the increased level of nicotine dependence among smokers with schizophrenia, and reduced access to treatments.292 People with schizophrenia also report smoking to manage stress and negative affect, and to maintain social relationships.62 They may also perceive themselves to be at lower risk of smoking-related disease.293
Healthcare services have traditionally condoned or encouraged smoking and failed to offer tobacco cessation interventions to patients with schizophrenia,62 mainly due to beliefs about the benefits of smoking to symptoms, stigma, lack of information, or perceived hopelessness regarding abstinence.294,295 However, in recent times there has been considerable interest in developing effective smoking treatment for this population,55 particularly in light of research showing that smoking is associated with poorer clinical outcomes.296,297 Guidelines have been published that include smoking cessation interventions for people with schizophrenia,124 and studies have highlighted that early interventions with young people at risk of psychosis can be effective.298 People who smoke with a psychotic disorder are capable of long-term reduction and abstinence with appropriate intervention and support.299 Once people with schizophrenia have successfully quit, the use of antipsychotics may need to be reviewed, as tobacco smoke can differentially affect drug metabolism and the effects of antipsychotic medications.8,300
Several early reviews found evidence for the use of bupropion and/or varenicline to promote cessation among people with schizophrenia.295,301 Results from a large randomised controlled trial were published in 2016, which found that varenicline was more effective than bupropion and nicotine patch in smokers both with and without psychiatric disorders (including schizophrenia), whereas bupropion and nicotine patch were similarly effective, and both more so than placebo. The authors also concluded that the medications can be used safely by psychiatrically stable people who smoke; there was no increase in neuropsychiatric adverse events attributable to varenicline or bupropion relative to nicotine patch or placebo.131 Although a review of the study by the FDA raised concerns of a possible increased risk of neuropsychiatric events in patients with psychiatric history in the varenicline or bupropion group compared to placebo,302 subsequent randomised controlled trials,303,304 reviews,305 and meta-analyses306-308 have supported the safety and efficacy of varenicline for reducing smoking in people with schizophrenia. A 2017 review recommends that people with schizophrenia who smoke should receive varenicline, bupropion with or without NRT, or NRT, all in combination with behavioural treatment for at least 12 weeks. Maintenance pharmacotherapy may reduce relapse and improve sustained abstinence rates. It notes that controlled trials in people with schizophrenia who smoke consistently show no greater rate of neuropsychiatric adverse events with pharmacotherapies than with placebo.309 A 2018 review concluded that varenicline appears to be an effective and safe drug for smoking cessation in patients with schizophrenia,307 and another in 2020 concluded that maintenance pharmacotherapy with varenicline and sustained-release bupropion are both well-tolerated among people with schizophrenia.310 Findings from a 2020 meta-analysis suggest that varenicline might be superior to bupropion for people with schizophrenia, but calls for more comparative/combination studies.308 Several recent reviews have also supported the effectiveness of multimodal interventions (i.e., combining pharmacological and non-pharmacological treatments) for reducing smoking among people with schizophrenia without worsening psychiatric symptoms.311,312
There has also been some interest in the use of electronic cigarettes for smoking cessation among people with schizophrenia; however there is currently only very limited research on their efficacy.313 See Section 18.7 for further discussion. One review notes that nicotine is likely responsible for the potential role of smoking in the onset of schizophrenia, which should be considered in discussion of e-cigarettes.314
Medical and mental health professionals have traditionally overlooked the importance of addressing tobacco use with their patients.57 Smoking is often not asked about or recorded as a standard part of psychiatric assessment, and even when it is, inclusion of smoking cessation in treatment planning is often inconsistent.57,315,316 This may be partly due to the erroneous beliefs held by some mental health workers that smoking is one of the few pleasures clients have, that smoking reduces stress and anxiety,63,317 that those with mental illness are not motivated to quit,107 or that there are more pressing concerns for patients with acute psychiatric symptoms.90 They may also hold fatalistic views that smoking and failed quit attempts are inevitable.66
International evidence suggests that cessation support for inpatient smokers by staff is likely to be severely compromised by low levels of knowledge and awareness of tobacco dependence.318 Several Australian surveys have found strong support for the provision of smoking cessation treatment among mental health service staff;319,320 however staff report significant barriers to providing such care.319 Commonly cited barriers include inadequate resources, cultural norms, client resistance, and lack of training and confidence.256,321-326 More experienced staff, and those with tobacco cessation training, are more likely to help their clients quit smoking.316,327,328
Healthcare professionals, including physicians, psychiatrists, and psychologists, have an important role in the recognition and treatment of tobacco use disorders in patients with psychiatric illnesses, and providing cessation treatment for all patients who smoke should form part of routine care.8,329,330 Australians with mental illness who smoke report that mental health professionals are a preferred and trusted source of cessation information,144 therefore offering smoking cessation advice should receive a higher priority in everyday clinical practice for patients with a mental health diagnosis.331 Encouraging longitudinal research in the US found that people who smoke who had seen mental health professionals had higher odds of having made attempts to quit in the past year, and were more likely to have used cessation assistance.332 However, another longitudinal US study looking only at psychiatrists found that they are screening for tobacco use at declining rates, and the proportion of people who smoke provided with treatment remains low,333 and a UK study found that smoking cessation medication prescribing appeared to be declining in primary care.334 Australian research also found that the provision of cessation interventions in acute psychiatric units is inconsistent and generally suboptimal.335
As in the overall population, people with mental illness should be given advice and support to quit using the 5As framework.336 Given that people with mental illness are often highly nicotine dependent, and are more likely to socialise with people who smoke, more intensive interventions may have greater success. This might involve NRT or other pharmacotherapies, as well as referral to a specialised individual program, such as the Quitline, or a group program. The integration of cessation treatment into existing care by health professionals results in greater engagement, greater use of cessation pharmacotherapy, and increased likelihood of abstinence.138,337 An Australian study found that introducing a ’smokers’ clinic‘ to a mental health setting helped those with mental illness to reduce or quit smoking and led to a sustained increase in the delivery of cessation interventions among health professionals.132
Researchers have developed a comprehensive guide for healthcare professionals to integrate smoking cessation treatment into routine care, and note that by drawing on evidence-based methods such as behavioural support and CBT, smoking cessation can be addressed in a compassionate and respectful manner.51 There are a number of strategies that mental health services could implement to reduce smoking-related harms, including:
An important part of providing smoking cessation support for those with mental health disorders is for mental health services to develop comprehensive policy on smokefree environments, documenting tobacco use, and continuing support on discharge. This requires leadership from management, staff training, and consistency across services.339-341 An audit of an Australian psychiatric hospital found that the setting did not conform to current clinical practice guidelines as it often failed to document smoking status, despite nicotine dependence being the most commonly diagnosed psychiatric disorder.342 Another Australian study of public psychiatric inpatient units found that over one-third of inpatients started smoking during their admission, and that staff often provided cigarettes to patients. Only half of respondents reported that all patients were assessed for smoking status. The study suggests that failure of psychiatric services to provide smoking care is systematic and not related to particular types of services.343 System change models that address system-level barriers and promote changes in routine practice may therefore help improve cessation provision and outcomes.344 Research in Queensland found that a system change intervention that was supported by incentive payments improved the delivery of tobacco treatment in community psychiatry settings, and these improvements were maintained long-term even after removal of incentives.345 Another study in Queensland similarly found that implementation of a cessation intervention with a system change intervention led to sustained improvement in addressing smoking in adult inpatient psychiatry units.346
However, an Australian study published in 2015 found that adherence to smokefree policy in an inpatient psychiatric facility was poor, with more than four in five people who smoke still smoking, and only about half perceiving staff to be supportive of the policy.356 Two Australian studies have found that about only about half of psychiatric patients feel positively about bans,356,357 while another found that only about one quarter of mental health staff agreed with a total smoking ban.358 Compliance and enforcement can be challenging in the context of high smoking prevalence and complex needs of patients.359 Some patients also perceive the restrictions to be a form of punishment.360 There have been debates regarding the ethics of implementing complete smoking bans in psychiatric hospitals; proponents argue that the ‘smoking culture’ creates disproportionate harm among people with mental illness, while opponents argue that it is unethical to deprive patients of autonomy and impose treatment.361,362
Together, evidence suggests that there is a critical need to engage healthcare providers, policy-makers, and mental health advocates in the effort to increase access to:
References
1. Cooper J, Mancuso SG, Borland R, Slade T, Galletly C, et al. Tobacco smoking among people living with a psychotic illness: the second Australian Survey of Psychosis. Australian and New Zealand Journal of Psychiatry, 2012; 46(9):851-63. Available from: https://www.ncbi.nlm.nih.gov/pubmed/22645396
2. Williams JM, Steinberg ML, Griffiths KG, and Cooperman N. Smokers with behavioral health comorbidity should be designated a tobacco use disparity group. American Journal of Public Health, 2013; 103(9):1549-55. Available from: https://www.ncbi.nlm.nih.gov/pubmed/23865661
3. Forman-Hoffman VL, Hedden SL, Glasheen C, Davies C, and Colpe LJ. The role of mental illness on cigarette dependence and successful quitting in a nationally representative, household-based sample of U.S. adults. Annals of Epidemiology, 2016; 26(7):447-54. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27247163
4. Australian Institute of Health and Welfare. National Drug Strategy Household Survey 2022–2023. Canberra: AIHW, 2024. Available from: https://www.aihw.gov.au/reports/illicit-use-of-drugs/national-drug-strategy-household-survey
5. Australian Bureau of Statistics. National Study of Mental Health and Wellbeing 2020-21. ABS, 2022. Available from: https://www.abs.gov.au/statistics/health/mental-health/national-study-mental-health-and-wellbeing/latest-release
6. Greenhalgh EM, Brennan E, Segan C, and Scollo M. Monitoring changes in smoking and quitting behaviours among Australians with and without mental illness over 15 years. Australian and New Zealand Journal of Public Health, 2022; 46(2):223-9. Available from: https://www.ncbi.nlm.nih.gov/pubmed/34821438
7. Australian Institute of Health and Welfare. National Drug Strategy Household Survey, 2022-2023. ADA Dataverse, 2024. Available from: https://doi.org/10.26193/U6LY7H.
8. Mendelsohn CP, Kirby DP, and Castle DJ. Smoking and mental illness. An update for psychiatrists. Australas Psychiatry, 2015; 23(1):37-43. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25512967
9. Jablensky A, McGrath J, Herrman H, Castle D, Gureje O, et al. People living with psychotic Illness: an Australian study 1997-98. Mental Health Branch, Commonwealth Department of Health and Aged Care, Canberra, 1999.
10. Australian Bureau of Statistics. National Health Survey. 2022. Available from: https://www.abs.gov.au/statistics/health/health-conditions-and-risks/national-health-survey/2022
11. Baker A, Ivers R, Bowman J, Butler T, Kay-Lambkin F, et al. Where there's smoke, there's fire: high prevalence of smoking among some sub-populations and recommendations for intervention. Drug and Alcohol Review, 2006; 25:85–96. Available from: http://www.informaworld.com/smpp/content~content=a741424195~db=all~order=page
12. Scully M, Bain E, Koh I, Wakefield M, and Durkin S. ASSAD 2022/2023: Australian secondary school students’ use of tobacco and e-cigarettes. Centre of Behavioural Research in Cancer, Cancer Council Victoria, 2023. Available from: https://www.health.gov.au/sites/default/files/2023-11/secondary-school-students-use-of-tobacco-and-e-cigarettes-2022-2023.pdf
13. Greenhalgh E and Scollo M. Alcohol and tobacco use in Victoria and Australia: Results from the 2019 National Drug Strategy Household Survey. Melbourne: Centre for Behavioural Research in Cancer, Cancer Council Victoria, 2021.
14. Smith PH, Chhipa M, Bystrik J, Roy J, Goodwin RD, et al. Cigarette smoking among those with mental disorders in the US population: 2012-2013 update. Tobacco Control, 2020; 29(1):29-35. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30377242
15. Richardson S, McNeill A, and Brose LS. Smoking and quitting behaviours by mental health conditions in Great Britain (1993-2014). Addictive Behaviors, 2019; 90:14-9. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30352340
16. DeHay T, Morris C, May MG, Devine K, and Waxmonsky J. Tobacco use in youth with mental illnesses. Journal of Behavioral Medicine, 2012; 35(2):139-48. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21479646
17. Lee J and Thrul J. Trends in opioid misuse by cigarette smoking status among US adolescents: Results from National Survey on Drug Use and Health 2015-2018. Preventive Medicine, 2021; 153:106829. Available from: https://www.ncbi.nlm.nih.gov/pubmed/34624387
18. Cotton SM, Sharmin S, Gao CX, Brown E, Menssink JM, et al. Prevalence and Correlates of Tobacco Use in Young People Presenting to Australian Primary Mental Health Services. Nicotine & Tobacco Research, 2023; 25(4):682-91. Available from: https://www.ncbi.nlm.nih.gov/pubmed/35665823
19. Brown E, O'Donoghue B, White SL, Chanen A, Bedi G, et al. Tobacco smoking in young people seeking treatment for mental ill-health: what are their attitudes, knowledge and behaviours towards quitting? Ir J Psychol Med, 2021; 38(1):30-9. Available from: https://www.ncbi.nlm.nih.gov/pubmed/32317033
20. Hermens DF, Scott EM, White D, Lynch M, Lagopoulos J, et al. Frequent alcohol, nicotine or cannabis use is common in young persons presenting for mental healthcare: a cross-sectional study. BMJ Open, 2013; 3(2):e002229. Available from: https://www.ncbi.nlm.nih.gov/pubmed/23381649
21. Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, et al. Smoking and mental illness: A population-based prevalence study. Journal of the American Medical Association, 2000; 284(20):2606-10. Available from: https://www.ncbi.nlm.nih.gov/pubmed/11086367
22. Grant BF, Hasin DS, Chou SP, Stinson FS, and Dawson DA. Nicotine dependence and psychiatric disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry, 2004; 61(11):1107-15. Available from: https://www.ncbi.nlm.nih.gov/pubmed/15520358
23. Ashton M, Miller CL, Bowden JA, and Bertossa S. People with mental illness can tackle tobacco. Australian and New Zealand Journal of Psychiatry, 2010; 44(11):1021-8. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21034185
24. Baker A, Richmond R, Haile M, Lewin TJ, Carr VJ, et al. Characteristics of smokers with a psychotic disorder and implications for smoking interventions. Psychiatry Res, 2007; 150(2):141-52. Available from: https://www.ncbi.nlm.nih.gov/pubmed/17289155
25. Lawrence D and Williams JM. Trends in Smoking Rates by Level of Psychological Distress-Time Series Analysis of US National Health Interview Survey Data 1997-2014. Nicotine & Tobacco Research, 2016; 18(6):1463-70. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26705303
26. Steinberg ML, Williams JM, and Li Y. Poor Mental Health and Reduced Decline in Smoking Prevalence. American Journal of Preventive Medicine, 2015; 49(3):362-9. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26071864
27. Weinberger AH, Gbedemah M, Wall MM, Hasin DS, Zvolensky MJ, et al. Cigarette use is increasing among people with illicit substance use disorders in the United States, 2002-14: emerging disparities in vulnerable populations. Addiction, 2018; 113(4):719-28. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29265574
28. Dickerson F, Schroeder J, Katsafanas E, Khushalani S, Origoni AE, et al. Cigarette Smoking by Patients With Serious Mental Illness, 1999-2016: An Increasing Disparity. Psychiatric Services, 2018; 69(2):147-53. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28945183
29. Australian Institute of Health and Welfare. National Drug Strategy Household Survey 2019. Drug Statistics series no. 32 Cat. no. PHE 270 Canberra: AIHW, 2020. Available from: https://www.aihw.gov.au/getmedia/3564474e-f7ad-461c-b918-7f8de03d1294/aihw-phe-270-NDSHS-2019.pdf.aspx?inline=true
30. Kulik MC and Glantz SA. Softening Among U.S. Smokers With Psychological Distress: More Quit Attempts and Lower Consumption as Smoking Drops. American Journal of Preventive Medicine, 2017; 53(6):810-7. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29029966
31. Weinberger AH, Gbedemah M, and Goodwin RD. Cigarette smoking quit rates among adults with and without alcohol use disorders and heavy alcohol use, 2002-2015: A representative sample of the United States population. Drug and Alcohol Dependence, 2017; 180:204-7. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28918239
32. Han B, Volkow ND, Blanco C, Tipperman D, Einstein EB, et al. Trends in Prevalence of Cigarette Smoking Among US Adults With Major Depression or Substance Use Disorders, 2006-2019. Journal of the American Medical Association, 2022; 327(16):1566-76. Available from: https://www.ncbi.nlm.nih.gov/pubmed/35471512
33. Australian Bureau of Statistics. TableBuilder. Available from: http://www.abs.gov.au/websitedbs/d3310114.nsf/home/about+tablebuilder
34. Australian Bureau of Statistics. 4364.0.55.001 - Australian Health Survey: First Results, 2011–12. 2012. Available from: http://www.abs.gov.au/ausstats/abs@.nsf/lookup/4364.0.55.001main+features12011-12
35. Australian Bureau of Statistics. 4364.0.55.001–National Health Survey: First Results, 2014–15 Available from: http://www.abs.gov.au/ausstats/abs@.nsf/Lookup/by%20Subject/4364.0.55.001~2014-15~Main%20Features~Key%20findings~1
36. Australian Bureau of Statistics. National Health Survey 2017–18: First results. 2018. Available from: https://www.abs.gov.au/statistics/health/health-conditions-and-risks/national-health-survey-first-results/2017-18
37. Australian Institute of Health Welfare. Australian Burden of Disease Study 2024. Canberra: AIHW, 2024. Available from: https://www.aihw.gov.au/reports/burden-of-disease/australian-burden-of-disease-study-2024
38. Lawrence D, Holman C, and Jablensky A. Duty to Care. Preventable physical illness in people with mental illness. Perth: The University of Western Australia, 2001.
39. Lawrence D, Hancock KJ, and Kisely S. The gap in life expectancy from preventable physical illness in psychiatric patients in Western Australia: retrospective analysis of population based registers. British Medical Journal, 2013; 346:f2539. Available from: https://www.ncbi.nlm.nih.gov/pubmed/23694688
40. Tam J, Warner KE, and Meza R. Smoking and the Reduced Life Expectancy of Individuals With Serious Mental Illness. American Journal of Preventive Medicine, 2016; 51(6):958-66. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27522471
41. Pedersen ALW, Lindekilde CR, Andersen K, Hjorth P, and Gildberg FA. Health behaviours of forensic mental health service users, in relation to smoking, alcohol consumption, dietary behaviours and physical activity-A mixed methods systematic review. J Psychiatr Ment Health Nurs, 2021; 28(3):444-61. Available from: https://www.ncbi.nlm.nih.gov/pubmed/32916759
42. Chesney E, Robson D, Patel R, Shetty H, Richardson S, et al. The impact of cigarette smoking on life expectancy in schizophrenia, schizoaffective disorder and bipolar affective disorder: An electronic case register cohort study. Schizophr Res, 2021; 238:29-35. Available from: https://www.ncbi.nlm.nih.gov/pubmed/34563995
43. Tam J, Taylor GMJ, Zivin K, Warner KE, and Meza R. Modeling smoking-attributable mortality among adults with major depression in the United States. Preventive Medicine, 2020; 140:106241. Available from: https://www.ncbi.nlm.nih.gov/pubmed/32860820
44. Tam J, Warner KE, Zivin K, Taylor GMJ, and Meza R. The Potential Impact of Widespread Cessation Treatment for Smokers With Depression. American Journal of Preventive Medicine, 2021; 61(5):674-82. Available from: https://www.ncbi.nlm.nih.gov/pubmed/34244005
45. Taylor G, McNeill A, Girling A, Farley A, Lindson-Hawley N, et al. Change in mental health after smoking cessation: systematic review and meta-analysis. British Medical Journal, 2014; 348:g1151. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24524926
46. Taylor GM, Lindson N, Farley A, Leinberger-Jabari A, Sawyer K, et al. Smoking cessation for improving mental health. Cochrane Database of Systematic Reviews, 2021; 3(3):CD013522. Available from: https://www.ncbi.nlm.nih.gov/pubmed/33687070
47. Meckel K and Rittenhouse K. The effect of smoking cessation on mental health: Evidence from a randomized trial. J Health Econ, 2025; 100:102969. Available from: https://www.ncbi.nlm.nih.gov/pubmed/39908648
48. Taylor GMJ and Treur JL. An application of the stress-diathesis model: A review about the association between smoking tobacco, smoking cessation, and mental health. Int J Clin Health Psychol, 2023; 23(1):100335. Available from: https://www.ncbi.nlm.nih.gov/pubmed/36247407
49. Liu NH, Wu C, Perez-Stable EJ, and Munoz RF. Longitudinal Association Between Smoking Abstinence and Depression Severity in Those With Baseline Current, Past, and No History of Major Depressive Episode in an International Online Tobacco Cessation Study. Nicotine & Tobacco Research, 2021; 23(2):267-75. Available from: https://www.ncbi.nlm.nih.gov/pubmed/32149344
50. Yonek JC, Meacham MC, Shumway M, Tolou-Shams M, and Satre DD. Smoking reduction is associated with lower alcohol consumption and depressive symptoms among young adults over one year. Drug and Alcohol Dependence, 2021; 227:108922. Available from: https://www.ncbi.nlm.nih.gov/pubmed/34364192
51. Taylor GMJ, Baker AL, Fox N, Kessler DS, Aveyard P, et al. Addressing concerns about smoking cessation and mental health: theoretical review and practical guide for healthcare professionals. BJPsych Adv, 2021; 27(2):85-95. Available from: https://www.ncbi.nlm.nih.gov/pubmed/34513007
52. Salt V and Osborne C. Mental health, smoking and poverty: benefits of supporting smokers to quit. BJPsych Bull, 2020; 44(5):213-8. Available from: https://www.ncbi.nlm.nih.gov/pubmed/32847647
53. Rogers ES. Financial Distress and Smoking-induced Deprivation in Smokers with Depression. American Journal of Health Behavior, 2019; 43(1):219-27. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30522579
54. Lawn S. Australians with mental illness who smoke. The British Journal of Psychiatry, 2001; 178(1):85. Available from: https://www.ncbi.nlm.nih.gov/pubmed/11136222
55. Minichino A, Bersani FS, Calo WK, Spagnoli F, Francesconi M, et al. Smoking behaviour and mental health disorders--mutual influences and implications for therapy. International Journal of Environmental Research and Public Health, 2013; 10(10):4790-811. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24157506
56. Dwyer T, Bradshaw J, and Happell B. Comparison of mental health nurses' attitudes towards smoking and smoking behaviour. International Journal of Mental Health Nursing, 2009; 18(6):424-33. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19883414
57. Ragg M and Ahmed T, Smoke and mirrors: a review of the literature on smoking and mental illness. Tackiling Tobacco Program Research Series No 1 Sydney: Cancer Council NSW; 2008. Available from: http://www.cancerdirectory.com.au/resource/view?slug=Smoke-and-Mirrors-A-review-of-the-literature-on-smoking-and-mental-illness&page=1.
58. Hall SM and Prochaska JJ. Treatment of smokers with co-occurring disorders: emphasis on integration in mental health and addiction treatment settings. Annu Rev Clin Psychol, 2009; 5:409-31. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19327035
59. Lawn S and Pols R. Nicotine withdrawal: pathway to aggression and assault in the locked psychiatric ward? Australasian Psychiatry, 2003; 11(2):199–203. Available from: https://journals.sagepub.com/doi/abs/10.1046/j.1039-8562.2003.00548.x
60. Olivier D, Lubman D, and Fraser R. Tobacco smoking within psychiatric inpatient settings: biopsychosocial perspective. Australia and New Zealand Journal of Psychiatry, 2007; 41(7):572–80. Available from: http://www.informaworld.com/smpp/content~db=all?content=10.1080/00048670701392809
61. Aubin HJ, Rollema H, Svensson TH, and Winterer G. Smoking, quitting, and psychiatric disease: a review. Neurosci Biobehav Rev, 2012; 36(1):271-84. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21723317
62. Lum A, Skelton E, Wynne O, and Bonevski B. A Systematic Review of Psychosocial Barriers and Facilitators to Smoking Cessation in People Living With Schizophrenia. Front Psychiatry, 2018; 9:565. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30459658
63. Reilly P, Murphy L, and Alderton D. Challenging the smoking culture within a mental health service supportively. International Journal of Mental Health Nursing, 2006; 15(4):272–8. Available from: https://pubmed.ncbi.nlm.nih.gov/17064324/
64. Peckham E, Bradshaw TJ, Brabyn S, Knowles S, and Gilbody S. Exploring why people with SMI smoke and why they may want to quit: baseline data from the SCIMITAR RCT. J Psychiatr Ment Health Nurs, 2016; 23(5):282-9. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26147943
65. Trainor K and Leavey G. Barriers and Facilitators to Smoking Cessation Among People With Severe Mental Illness: A Critical Appraisal of Qualitative Studies. Nicotine & Tobacco Research, 2017; 19(1):14-23. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27613905
66. Twyman L, Cowles C, Walsberger SC, Baker AL, Bonevski B, et al. 'They're Going to Smoke Anyway': A Qualitative Study of Community Mental Health Staff and Consumer Perspectives on the Role of Social and Living Environments in Tobacco Use and Cessation. Front Psychiatry, 2019; 10:503. Available from: https://www.ncbi.nlm.nih.gov/pubmed/31379622
67. Chang LH, Whitfield JB, Liu M, Medland SE, Hickie IB, et al. Associations between polygenic risk for tobacco and alcohol use and liability to tobacco and alcohol use, and psychiatric disorders in an independent sample of 13,999 Australian adults. Drug and Alcohol Dependence, 2019; 205:107704. Available from: https://www.ncbi.nlm.nih.gov/pubmed/31731259
68. Peterson RE, Bigdeli TB, Ripke S, Bacanu SA, Gejman PV, et al. Genome-wide analyses of smoking behaviors in schizophrenia: Findings from the Psychiatric Genomics Consortium. Journal of Psychiatric Research, 2021; 137:215-24. Available from: https://www.ncbi.nlm.nih.gov/pubmed/33691233
69. Sagud M, Vuksan-Cusa B, Jaksic N, Mihaljevic-Peles A, Rojnic Kuzman M, et al. Smoking in Schizophrenia: an Updated Review. Psychiatr Danub, 2018; 30(Suppl 4):216-23. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29864763
70. Barkhuizen W, Dudbridge F, and Ronald A. Genetic overlap and causal associations between smoking behaviours and mental health. Sci Rep, 2021; 11(1):14871. Available from: https://www.ncbi.nlm.nih.gov/pubmed/34290290
71. Burke C, Taylor G, Freeman TP, Sallis H, Wootton RE, et al. Disentangling the effects of nicotine versus non-nicotine constituents of tobacco smoke on major depressive disorder: A multivariable Mendelian randomisation study. Addiction, 2025; 120(6):1240-52. Available from: https://www.ncbi.nlm.nih.gov/pubmed/39931798
72. Burke C, Freeman TP, Sallis H, Wootton RE, Burnley A, et al. Associations of cannabis use, tobacco use, and incident anxiety, mood, and psychotic disorders: a systematic review and meta-analysis. Psychological Medicine, 2024; 54(15):1-15. Available from: https://www.ncbi.nlm.nih.gov/pubmed/39620474
73. He M, Zhou J, Li X, and Wang R. Investigating the causal effects of smoking, sleep, and BMI on major depressive disorder and bipolar disorder: a univariable and multivariable two-sample Mendelian randomization study. Front Psychiatry, 2023; 14:1206657. Available from: https://www.ncbi.nlm.nih.gov/pubmed/37900287
74. Morisano D, Bacher I, Audrain-McGovern J, and George TP. Mechanisms underlying the comorbidity of tobacco use in mental health and addictive disorders. Can J Psychiatry, 2009; 54(6):356-67. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19527556
75. Manzella F, Maloney SE, and Taylor GT. Smoking in schizophrenic patients: A critique of the self-medication hypothesis. World J Psychiatry, 2015; 5(1):35-46. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25815253
76. Boggs DL, Surti TS, Esterlis I, Pittman B, Cosgrove K, et al. Minimal effects of prolonged smoking abstinence or resumption on cognitive performance challenge the "self-medication" hypothesis in schizophrenia. Schizophr Res, 2018; 194:62-9. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28392208
77. Kassel JD, Stroud LR, and Paronis CA. Smoking, stress, and negative affect: correlation, causation, and context across stages of smoking. Psychol Bull, 2003; 129(2):270-304. Available from: https://www.ncbi.nlm.nih.gov/pubmed/12696841
78. Coustals N, Martelli C, Brunet-Lecomte M, Petillion A, Romeo B, et al. Chronic smoking and cognition in patients with schizophrenia: A meta-analysis. Schizophr Res, 2020; 222:113-21. Available from: https://www.ncbi.nlm.nih.gov/pubmed/32507373
79. Wang YY, Wang S, Zheng W, Zhong BL, Ng CH, et al. Cognitive functions in smoking and non-smoking patients with schizophrenia: A systematic review and meta-analysis of comparative studies. Psychiatry Res, 2019; 272:155-63. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30583258
80. Huang H, Dong M, Zhang L, Zhong BL, Ng CH, et al. Psychopathology and extrapyramidal side effects in smoking and non-smoking patients with schizophrenia: Systematic review and meta-analysis of comparative studies. Prog Neuropsychopharmacol Biol Psychiatry, 2019; 92:476-82. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30794823
81. Gurillo P, Jauhar S, Murray RM, and MacCabe JH. Does tobacco use cause psychosis? Systematic review and meta-analysis. Lancet Psychiatry, 2015; 2(8):718-25. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26249303
82. Hunter A, Murray R, Asher L, and Leonardi-Bee J. The Effects of Tobacco Smoking, and Prenatal Tobacco Smoke Exposure, on Risk of Schizophrenia: A Systematic Review and Meta-Analysis. Nicotine & Tobacco Research, 2020; 22(1):3-10. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30102383
83. Hu Z, Cui E, Chen B, and Zhang M. Association between cigarette smoking and the risk of major psychiatric disorders: a systematic review and meta-analysis in depression, schizophrenia, and bipolar disorder. Front Med (Lausanne), 2025; 12:1529191. Available from: https://www.ncbi.nlm.nih.gov/pubmed/40018351
84. Lee B, Levy DE, Macy JT, Elam KK, Bidulescu A, et al. Smoking trajectories from adolescence to early adulthood as a longitudinal predictor of mental health in adulthood: evidence from 21 years of a nationally representative cohort. Addiction, 2022; 117(6):1727-36. Available from: https://www.ncbi.nlm.nih.gov/pubmed/34817100
85. Sanchez-Villegas A, Gea A, Lahortiga-Ramos F, Martinez-Gonzalez J, Molero P, et al. Bidirectional association between tobacco use and depression risk in the SUN cohort study. Adicciones, 2024; 36(1):41-52. Available from: https://www.ncbi.nlm.nih.gov/pubmed/34882246
86. Wootton RE, Richmond RC, Stuijfzand BG, Lawn RB, Sallis HM, et al. Evidence for causal effects of lifetime smoking on risk for depression and schizophrenia: a Mendelian randomisation study. Psychological Medicine, 2020; 50(14):2435-43. Available from: https://www.ncbi.nlm.nih.gov/pubmed/31689377
87. Stevenson J, Miller CL, Martin K, Mohammadi L, and Lawn S. Investigating the reciprocal temporal relationships between tobacco consumption and psychological disorders for youth: an international review. BMJ Open, 2022; 12(6):e055499. Available from: https://www.ncbi.nlm.nih.gov/pubmed/35697442
88. Vermeulen JM, Wootton RE, Treur JL, Sallis HM, Jones HJ, et al. Smoking and the risk for bipolar disorder: evidence from a bidirectional Mendelian randomisation study. The British Journal of Psychiatry, 2021; 218(2):88-94. Available from: https://www.ncbi.nlm.nih.gov/pubmed/31526406
89. Snell M, Harless D, Shin S, Cunningham P, and Barnes A. A longitudinal assessment of nicotine dependence, mental health, and attempts to quit Smoking: Evidence from waves 1-4 of the Population Assessment of Tobacco and Health (PATH) study. Addictive Behaviors, 2021; 115:106787. Available from: https://www.ncbi.nlm.nih.gov/pubmed/33383566
90. Prochaska JJ. Smoking and mental illness--breaking the link. New England Journal of Medicine, 2011; 365(3):196-8. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21774707
91. Tidey JW and Miller ME. Smoking cessation and reduction in people with chronic mental illness. British Medical Journal, 2015; 351:h4065. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26391240
92. Jenkins R, Bhugra D, Bebbington P, Brugha T, Farrell M, et al. Debt, income and mental disorder in the general population. Psychological Medicine, 2008; 38(10):1485-93. Available from: https://www.ncbi.nlm.nih.gov/pubmed/18184442
93. Department of Health, National mental health report. Australian Government; 2013.
94. Lawn S, Hersh D, Ward PR, Tsourtos G, Muller R, et al. 'I just saw it as something that would pull you down, rather than lift you up': resilience in never-smokers with mental illness. Health Education Research, 2011; 26(1):26-38. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21062967
95. Twyman L, Bonevski B, Paul C, and Bryant J. Perceived barriers to smoking cessation in selected vulnerable groups: a systematic review of the qualitative and quantitative literature. BMJ Open, 2014; 4(12):e006414. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25534212
96. Lawn S. Systematic barriers to quitting smoking among institutionalised public mental health service populations: a comparison of two Australian sites. The International Journal of Social Psychiatry, 2004; 50(3):201–15. Available from: https://pubmed.ncbi.nlm.nih.gov/15511114/
97. Sundgren E, Hallqvist J, and Fredriksson L. Health for smokers with schizophrenia - a struggle to maintain a dignified life. Disability and Rehabilitation, 2016; 38(5):416-22. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25958996
98. Ragg M, Gordon R, Ahmed T, and Allan J. The impact of smoking cessation on schizophrenia and major depression. Australas Psychiatry, 2013; 21(3):238-45. Available from: https://www.ncbi.nlm.nih.gov/pubmed/23616382
99. Banham L and Gilbody S. Smoking cessation in severe mental illness: what works? Addiction, 2010; 105(7):1176–89. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20491721
100. Bolam B, West R, and Gunnell D. Does smoking cessation cause depression and anxiety? Findings from the ATTEMPT cohort. Nicotine & Tobacco Research, 2011; 13(3):209-14. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21330275
101. Prochaska JJ, Delucchi K, and Hall SM. A meta-analysis of smoking cessation interventions with individuals in substance abuse treatment or recovery. Journal of Consulting and Clinical Psychology, 2004; 72(6):1144-56. Available from: https://www.ncbi.nlm.nih.gov/pubmed/15612860
102. Winhusen TM, Somoza EC, Brigham GS, Liu DS, Green CA, et al. Impact of attention-deficit/hyperactivity disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers: a randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry, 2010; 71(12):1680-8. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20492837
103. Covey LS, Hu MC, Winhusen T, Weissman J, Berlin I, et al. OROS-methylphenidate or placebo for adult smokers with attention deficit hyperactivity disorder: racial/ethnic differences. Drug and Alcohol Dependence, 2010; 110(1-2):156-9. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20219292
104. Covey LS, Hu MC, Winhusen T, Lima J, Berlin I, et al. Anxiety and Depressed Mood Decline Following Smoking Abstinence in Adult Smokers with Attention Deficit Hyperactivity Disorder. Journal of Substance Abuse Treatment, 2015; 59:104-8. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26272693
105. Yaworski D, Robinson J, Sareen J, and Bolton JM. The relation between nicotine dependence and suicide attempts in the general population. Can J Psychiatry, 2011; 56(3):161-70. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21443823
106. Hitsman B, Borrelli B, McChargue DE, Spring B, and Niaura R. History of depression and smoking cessation outcome: a meta-analysis. Journal of Consulting and Clinical Psychology, 2003; 71(4):657-63. Available from: https://www.ncbi.nlm.nih.gov/pubmed/12924670
107. Siru R, Hulse GK, and Tait RJ. Assessing motivation to quit smoking in people with mental illness: a review. Addiction, 2009; 104(5):719-33. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19413788
108. Kagabo R, Gordon AJ, and Okuyemi K. Smoking cessation in inpatient psychiatry treatment facilities: A review. Addictive Behaviors Reports, 2020; 11:100255. Available from: https://www.ncbi.nlm.nih.gov/pubmed/32467844
109. Brown CH, Medoff D, Dickerson FB, Fang LJ, Lucksted A, et al. Factors influencing implementation of smoking cessation treatment within community mental health centers. Journal of Dual Diagnosis, 2015; 11(2):145-50. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25985201
110. Cook BL, Wayne GF, Kafali EN, Liu Z, Shu C, et al. Trends in smoking among adults with mental illness and association between mental health treatment and smoking cessation. Journal of the American Medical Association, 2014; 311(2):172-82. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24399556
111. Tidey JW, Colby SM, and Xavier EM. Effects of smoking abstinence on cigarette craving, nicotine withdrawal, and nicotine reinforcement in smokers with and without schizophrenia. Nicotine & Tobacco Research, 2014; 16(3):326-34. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24113929
112. Prochaska JJ. Failure to treat tobacco use in mental health and addiction treatment settings: a form of harm reduction? Drug and Alcohol Dependence, 2010; 110(3):177-82. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20378281
113. Anzai N, Young-Wolff KC, and Prochaska JJ. Symptom severity and readiness to quit among hospitalized smokers with mental illness. Psychiatric Services, 2015; 66(4):443-4. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25828988
114. McNeill A. Smoking and mental health: a review of the literature. London: Smokefree London Programme, 2001. Available from: http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.622.6748&rep=rep1&type=pdf
115. Morris CD, Burns EK, Waxmonsky JA, and Levinson AH. Smoking cessation behaviors among persons with psychiatric diagnoses: results from a population-level state survey. Drug and Alcohol Dependence, 2014; 136:63-8. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24417963
116. Siru R, Hulse GK, Khan RJ, and Tait RJ. Motivation to quit smoking among hospitalised individuals with and without mental health disorders. Australian and New Zealand Journal of Psychiatry, 2010; 44(7):640-7. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20560851
117. Moeller-Saxone K. Cigarette smoking and interest in quitting among consumers at a Psychiatric Disability Rehabilitation and Support Service in Victoria. Australian and New Zealand Journal of Public Health, 2008; 32(5):479–81. Available from: http://onlinelibrary.wiley.com/doi/10.1111/j.1753-6405.2008.00283.x/abstract
118. Young-Wolff KC, Fromont SC, Delucchi K, Hall SE, Hall SM, et al. PTSD symptomatology and readiness to quit smoking among women with serious mental illness. Addictive Behaviors, 2014; 39(8):1231-4. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24813548
119. Dickerson F, Bennett M, Dixon L, Burke E, Vaughan C, et al. Smoking cessation in persons with serious mental illnesses: the experience of successful quitters. Psychiatric Rehabilitation Journal, 2011; 34(4):311-6. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21459747
120. Hitsman B, Moss TG, Montoya ID, and George TP. Treatment of tobacco dependence in mental health and addictive disorders. Can J Psychiatry, 2009; 54(6):368-78. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19527557
121. Talukder SR, Lappin JM, Boland V, McRobbie H, and Courtney RJ. Inequity in smoking cessation clinical trials testing pharmacotherapies: exclusion of smokers with mental health disorders. Tobacco Control, 2023; 32(4):489-96. Available from: https://www.ncbi.nlm.nih.gov/pubmed/34862325
122. Cavazos-Rehg PA, Breslau N, Hatsukami D, Krauss MJ, Spitznagel EL, et al. Smoking cessation is associated with lower rates of mood/anxiety and alcohol use disorders. Psychological Medicine, 2014; 44(12):2523-35. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25055171
123. Correa JB, Lawrence D, McKenna BS, Gaznick N, Saccone PA, et al. Psychiatric Comorbidity and Multimorbidity in the EAGLES Trial: Descriptive Correlates and Associations With Neuropsychiatric Adverse Events, Treatment Adherence, and Smoking Cessation. Nicotine & Tobacco Research, 2021; 23(10):1646-55. Available from: https://www.ncbi.nlm.nih.gov/pubmed/33788933
124. The Royal Australian College of General Practitioners, Supporting smoking cessation: a guide for health professionals. Melbourne: RACGP; 2014. Available from: http://www.racgp.org.au/your-practice/guidelines/smoking-cessation/.
125. Patnode CD, Henderson JT, Thompson JH, Senger CA, Fortmann SP, et al. Behavioral Counseling and Pharmacotherapy Interventions for Tobacco Cessation in Adults, Including Pregnant Women: A Review of Reviews for the U.S. Preventive Services Task Force. Annals of Internal Medicine, 2015; 163(8):608-21. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26389650
126. Lightfoot K, Panagiotaki G, and Nobes G. Effectiveness of psychological interventions for smoking cessation in adults with mental health problems: A systematic review. British Journal of Health Psychology, 2020; 25(3):615-38. Available from: https://www.ncbi.nlm.nih.gov/pubmed/32678937
127. Crabb AB, Allen J, and Taylor G. What if I fail? Unsuccessful smoking cessation attempts and symptoms of depression and anxiety: a systematic review and meta-analysis. BMJ Open, 2025; 15(5):e091419. Available from: https://www.ncbi.nlm.nih.gov/pubmed/40316352
128. Talukder S, Lappin JM, Boland VC, Weaver N, McRobbie H, et al. Receipt of the 5As intervention for smoking cessation among people with and without mental health disorders. Journal of Psychiatric Research, 2024; 179:1-7. Available from: https://www.ncbi.nlm.nih.gov/pubmed/39213719
129. Sprenger S and Anderson JS. Dying to Quit: Understanding the Burden of Tobacco in Psychiatric Patients-A Clinical Review. J Psychiatr Pract, 2024; 30(1):23-31. Available from: https://www.ncbi.nlm.nih.gov/pubmed/38227724
130. Oliveira P, Ribeiro J, Donato H, and Madeira N. Smoking and antidepressants pharmacokinetics: a systematic review. Annals of General Psychiatry, 2017; 16:17. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28286537
131. Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet, 2016; 387(10037):2507-20. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27116918
132. Davis A, Ngo H, and Coleman M. An evaluation of a pilot specialist smoking cessation clinic in a mental health setting. Australas Psychiatry, 2019; 27(3):275-8. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30507301
133. Johnson SE, Mitrou F, Lawrence D, Zubrick SR, Wolstencroft K, et al. Feasibility of a Consumer Centred Tobacco Management intervention in Community Mental Health Services in Australia. Community Ment Health J, 2020; 56(7):1354-65. Available from: https://www.ncbi.nlm.nih.gov/pubmed/32036516
134. Twyman L, Walsberger S, Baker AL, Ahmadi S, Oldmeadow C, et al. Outcomes of an organisational change program aimed at increasing smoking cessation support within Australian community managed mental health organisations: A cluster randomised controlled trial. Addiction, 2025; 120(5):937-50. Available from: https://www.ncbi.nlm.nih.gov/pubmed/39987579
135. Fibbins H, Ward PB, Morell R, Lederman O, Teasdale S, et al. Evaluation of a smoking cessation program for adults with severe mental illness in a public mental health service. J Psychiatr Ment Health Nurs, 2024; 31(6):990-7. Available from: https://www.ncbi.nlm.nih.gov/pubmed/38551076
136. Lappin JM, Thomas D, Curtis J, Blowfield S, Gatsi M, et al. Targeted Intervention to Reduce Smoking among People with Severe Mental Illness: Implementation of a Smoking Cessation Intervention in an Inpatient Mental Health Setting. Medicina (Kaunas), 2020; 56(4). Available from: https://www.ncbi.nlm.nih.gov/pubmed/32344790
137. Plever S, McCarthy I, Anzolin M, Emmerson B, Allan J, et al. Queensland smoking care in adult acute mental health inpatient units: Supporting practice change. Australian and New Zealand Journal of Psychiatry, 2020; 54(9):919-27. Available from: https://www.ncbi.nlm.nih.gov/pubmed/32375495
138. Skelton E, Tzelepis F, Shakeshaft A, Guillaumier A, McCrabb S, et al. Integrating smoking cessation care in alcohol and other drug treatment settings using an organizational change intervention: a systematic review. Addiction, 2018; 113(12):2158-72. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29920839
139. Taylor GMJ, Sawyer K, Jacobsen P, Freeman TP, Blackwell A, et al. intEgrating Smoking Cessation treatment As part of usual Psychological care for dEpression and anxiety (ESCAPE): A randomised and controlled, multi-centre, acceptability and feasibility trial with nested qualitative methods. Addiction, 2025; 120(5):922-36. Available from: https://www.ncbi.nlm.nih.gov/pubmed/40068701
140. Stockings EA, Bowman JA, Baker AL, Terry M, Clancy R, et al. Impact of a postdischarge smoking cessation intervention for smokers admitted to an inpatient psychiatric facility: a randomized controlled trial. Nicotine & Tobacco Research, 2014; 16(11):1417-28. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24939916
141. Schwindt R, Hudmon KS, Knisely M, Davis L, and Pike C. Impact of Tobacco Quitlines on Smoking Cessation in Persons With Mental Illness: A Systematic Review. J Drug Educ, 2017; 47(1-2):68-81. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29534595
142. Baker AL, Richmond R, Kay-Lambkin FJ, Filia SL, Castle D, et al. Randomized Controlled Trial of a Healthy Lifestyle Intervention Among Smokers With Psychotic Disorders. Nicotine & Tobacco Research, 2015; 17(8):946-54. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25744962
143. Segan CJ, Baker AL, Turner A, and Williams JM. Nicotine Withdrawal, Relapse of Mental Illness, or Medication Side-Effect? Implementing a Monitoring Tool for People With Mental Illness Into Quitline Counseling. J Dual Diagn, 2017; 13(1):60-6. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28067594
144. Sharma-Kumar R, Meurk C, Ford P, Beere D, and Gartner C. Are Australian smokers with mental illness receiving adequate smoking cessation and harm reduction information? International Journal of Mental Health Nursing, 2018; 27(6):1673-88. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29718549
145. Sharma-Kumar R, Puljevic C, Morphett K, Meurk C, and Gartner C. The Acceptability and Effectiveness of Videos Promoting Smoking Cessation Among Australians Experiencing Mental Illness. Health Educ Behav, 2022; 49(3):506-15. Available from: https://www.ncbi.nlm.nih.gov/pubmed/34496656
146. van der Meer RM, Willemsen MC, Smit F, and Cuijpers P. Smoking cessation interventions for smokers with current or past depression. Cochrane Database of Systematic Reviews, 2013; 8(8):CD006102. Available from: https://www.ncbi.nlm.nih.gov/pubmed/23963776
147. Weinberger AH, Pilver CE, Desai RA, Mazure CM, and McKee SA. The relationship of major depressive disorder and gender to changes in smoking for current and former smokers: longitudinal evaluation in the US population. Addiction, 2012; 107(10):1847-56. Available from: https://www.ncbi.nlm.nih.gov/pubmed/22429388
148. Khaled SM, Bulloch AG, Williams JV, Lavorato DH, and Patten SB. Major depression is a risk factor for shorter time to first cigarette irrespective of the number of cigarettes smoked per day: evidence from a National Population Health Survey. Nicotine & Tobacco Research, 2011; 13(11):1059-67. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21832274
149. van der Meer RM, Willemsen MC, Smit F, and Cuijpers P. Smoking cessation interventions for smokers with current or past depression. Cochrane Database of Systematic Reviews, 2006; 3:CD006102. Available from: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006102/abstract
150. Gravely S, Driezen P, Shahab L, McClure EA, Hyland A, et al. Associations of Cannabis Use, High-Risk Alcohol Use, and Depressive Symptomology with Motivation and Attempts to Quit Cigarette Smoking Among Adults: Findings from the 2020 ITC Four Country Smoking and Vaping Survey. Int J Ment Health Addict, 2025; 23(3):2021-45. Available from: https://www.ncbi.nlm.nih.gov/pubmed/40703248
151. Cooper J, Borland R, McKee SA, Yong HH, and Dugue PA. Depression motivates quit attempts but predicts relapse: differential findings for gender from the International Tobacco Control Study. Addiction, 2016; 111(8):1438-47. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26888199
152. Morozova M, Rabin RA, and George TP. Co-morbid tobacco use disorder and depression: A re-evaluation of smoking cessation therapy in depressed smokers. American Journal on Addictions, 2015; 24(8):687-94. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26354720
153. Guo Y and Yan J. Association between tobacco smoke exposure and depression: the NHANES 2005-2018 and Mendelian randomization study. Arch Public Health, 2024; 82(1):100. Available from: https://www.ncbi.nlm.nih.gov/pubmed/38961510
154. Secades-Villa R, Gonzalez-Roz A, Garcia-Perez A, and Becona E. Psychological, pharmacological, and combined smoking cessation interventions for smokers with current depression: A systematic review and meta-analysis. PLoS One, 2017; 12(12):e0188849. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29206852
155. Aldi GA, Bertoli G, Ferraro F, Pezzuto A, and Cosci F. Effectiveness of pharmacological or psychological interventions for smoking cessation in smokers with major depression or depressive symptoms: A systematic review of the literature. Substance Abuse, 2018; 39(3):289-306. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29436984
156. Hitsman B, Papandonatos GD, Gollan JK, Huffman MD, Niaura R, et al. Efficacy and safety of combination behavioral activation for smoking cessation and varenicline for treating tobacco dependence among individuals with current or past major depressive disorder: A 2 x 2 factorial, randomized, placebo-controlled trial. Addiction, 2023; 118(9):1710-25. Available from: https://www.ncbi.nlm.nih.gov/pubmed/37069490
157. Anthenelli RM, Morris C, Ramey TS, Dubrava SJ, Tsilkos K, et al. Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial. Annals of Internal Medicine, 2013; 159(6):390-400. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24042367
158. Evins AE, Benowitz NL, West R, Russ C, McRae T, et al. Neuropsychiatric Safety and Efficacy of Varenicline, Bupropion, and Nicotine Patch in Smokers With Psychotic, Anxiety, and Mood Disorders in the EAGLES Trial. J Clin Psychopharmacol, 2019; 39(2):108-16. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30811371
159. Kypriotakis G, Cinciripini PM, Green CE, Lawrence D, Anthenelli RM, et al. Effects of Varenicline, Bupropion, Nicotine Patch, and Placebo on Treating Smoking Among Persons With Current or Past Major Depressive Disorder: Secondary Analysis of a Double-Blind, Randomized, Placebo-Controlled Trial. American Journal of Psychiatry, 2025; 182(2):174-86. Available from: https://www.ncbi.nlm.nih.gov/pubmed/39659160
160. Cinciripini PM, Kypriotakis G, Green C, Lawrence D, Anthenelli RM, et al. The effects of varenicline, bupropion, nicotine patch, and placebo on smoking cessation among smokers with major depression: A randomized clinical trial. Depress Anxiety, 2022; 39(5):429-40. Available from: https://www.ncbi.nlm.nih.gov/pubmed/35535436
161. Marchal-Mateos MI, Lopez-Nunez C, and Fernandez-Artamendi S. Effectiveness of Contingency Management in Tobacco Smokers with Depressive Symptoms: A Systematic Review. Substance Use and Misuse, 2024; 59(5):792-804. Available from: https://www.ncbi.nlm.nih.gov/pubmed/38268117
162. Ziedonis D, Hitsman B, Beckham JC, Zvolensky M, Adler LE, et al. Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report. Nicotine & Tobacco Research, 2008; 10(12):1691-715. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19023823
163. G SC, C RG, M JZ, M ML, N BS, et al. Obsessive-compulsive symptoms and cigarette smoking: an initial cross-sectional test of mechanisms of co-occurrence. Cogn Behav Ther, 2020; 49(5):385-97. Available from: https://www.ncbi.nlm.nih.gov/pubmed/32324104
164. Akbari M, Seydavi M, Chasson GS, Leventhal AM, and Lockwood MI. Global prevalence of smoking among individuals with obsessive-compulsive disorder and symptoms: a systematic review and meta-analysis. Health Psychol Rev, 2023; 17(3):505-19. Available from: https://www.ncbi.nlm.nih.gov/pubmed/36173036
165. Petroulia I, Kyriakos CN, Papadakis S, Tzavara C, Filippidis FT, et al. Patterns of tobacco use, quit attempts, readiness to quit and self-efficacy among smokers with anxiety or depression: Findings among six countries of the EUREST-PLUS ITC Europe Surveys. Tobacco Induced Diseases, 2018; 16:A9. Available from: https://www.ncbi.nlm.nih.gov/pubmed/31516463
166. Piper ME, Cook JW, Schlam TR, Jorenby DE, and Baker TB. Anxiety diagnoses in smokers seeking cessation treatment: relations with tobacco dependence, withdrawal, outcome and response to treatment. Addiction, 2011; 106(2):418-27. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20973856
167. Kimbrel NA, Morissette SB, Gulliver SB, Langdon KJ, and Zvolensky MJ. The effect of social anxiety on urge and craving among smokers with and without anxiety disorders. Drug and Alcohol Dependence, 2014; 135:59-64. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24331637
168. Ayers CR, Heffner JL, Russ C, Lawrence D, McRae T, et al. Efficacy and safety of pharmacotherapies for smoking cessation in anxiety disorders: Subgroup analysis of the randomized, active- and placebo-controlled EAGLES trial. Depress Anxiety, 2020; 37(3):247-60. Available from: https://www.ncbi.nlm.nih.gov/pubmed/31850603
169. Poorolajal J and Darvishi N. Smoking and Suicide: A Meta-Analysis. PLoS One, 2016; 11(7):e0156348. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27391330
170. Echeverria I, Cotaina M, Jovani A, Mora R, Haro G, et al. Proposal for the Inclusion of Tobacco Use in Suicide Risk Scales: Results of a Meta-Analysis. International Journal of Environmental Research and Public Health, 2021; 18(11). Available from: https://www.ncbi.nlm.nih.gov/pubmed/34198855
171. Sankaranarayanan A, Clark V, Baker A, Palazzi K, Lewin TJ, et al. Reducing smoking reduces suicidality among individuals with psychosis: Complementary outcomes from a Healthy Lifestyles intervention study. Psychiatry Res, 2016; 243:407-12. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27450743
172. Icick R, Melle I, Etain B, Ringen PA, Aminoff SR, et al. Tobacco smoking and other substance use disorders associated with recurrent suicide attempts in bipolar disorder. J Affect Disord, 2019; 256:348-57. Available from: https://www.ncbi.nlm.nih.gov/pubmed/31202989
173. Pietschnig J, Oberleiter S, and Kohler MD. Smoking behavior is associated with suicidality in individuals with psychosis and bipolar disorder: a systematic quantitative review and meta-analysis. Front Psychol, 2024; 15:1369669. Available from: https://www.ncbi.nlm.nih.gov/pubmed/39328818
174. Wilhelm K, Handley T, and Reddy P. A case for identifying smoking in presentations to the emergency department with suicidality. Australas Psychiatry, 2018; 26(2):176-80. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29417825
175. Willcutt EG. The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review. Neurotherapeutics, 2012; 9(3):490-9. Available from: https://www.ncbi.nlm.nih.gov/pubmed/22976615
176. Schoenfelder EN, Faraone SV, and Kollins SH. Stimulant treatment of ADHD and cigarette smoking: a meta-analysis. Pediatrics, 2014; 133(6):1070-80. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24819571
177. McClernon FJ and Kollins SH. ADHD and smoking: from genes to brain to behavior. Annals of the New York Academy of Sciences, 2008; 1141:131-47. Available from: https://www.ncbi.nlm.nih.gov/pubmed/18991955
178. Lee SS, Humphreys KL, Flory K, Liu R, and Glass K. Prospective association of childhood attention-deficit/hyperactivity disorder (ADHD) and substance use and abuse/dependence: a meta-analytic review. Clin Psychol Rev, 2011; 31(3):328-41. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21382538
179. Kollins SH, McClernon FJ, and Fuemmeler BF. Association between smoking and attention-deficit/hyperactivity disorder symptoms in a population-based sample of young adults. Arch Gen Psychiatry, 2005; 62(10):1142-7. Available from: https://www.ncbi.nlm.nih.gov/pubmed/16203959
180. Mitchell JT, Howard AL, Belendiuk KA, Kennedy TM, Stehli A, et al. Cigarette Smoking Progression Among Young Adults Diagnosed With ADHD in Childhood: A 16-year Longitudinal Study of Children With and Without ADHD. Nicotine & Tobacco Research, 2019; 21(5):638-47. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29538764
181. US Department of Health and Human Services. The health consequences of smoking: a report of the Surgeon General. Atlanta, Georgia: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2004. Available from: http://www.cdc.gov/tobacco/data_statistics/sgr/index.htm
182. Kollins SH, Sweitzer MM, McClernon FJ, and Perkins KA. Increased subjective and reinforcing effects of initial nicotine exposure in young adults with attention deficit hyperactivity disorder (ADHD) compared to matched peers: results from an experimental model of first-time tobacco use. Neuropsychopharmacology, 2020; 45(5):851-6. Available from: https://www.ncbi.nlm.nih.gov/pubmed/31785588
183. van Amsterdam J, van der Velde B, Schulte M, and van den Brink W. Causal Factors of Increased Smoking in ADHD: A Systematic Review. Substance Use and Misuse, 2018; 53(3):432-45. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29039714
184. Luo SX, Covey LS, Hu MC, Winhusen TM, and Nunes EV. Differential Posttreatment Outcomes of Methylphenidate for Smoking Cessation for Individuals With ADHD. American Journal on Addictions, 2019; 28(6):497-502. Available from: https://www.ncbi.nlm.nih.gov/pubmed/31538372
185. Luo SX, Wall M, Covey L, Hu MC, Scodes JM, et al. Exploring longitudinal course and treatment-baseline severity interactions in secondary outcomes of smoking cessation treatment in individuals with attention-deficit hyperactivity disorder. American Journal of Drug and Alcohol Abuse, 2018; 44(6):653-9. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29370538
186. Wilens TE, Spencer TJ, Biederman J, Girard K, Doyle R, et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. American Journal of Psychiatry, 2001; 158(2):282-8. Available from: https://www.ncbi.nlm.nih.gov/pubmed/11156812
187. Bidwell LC, Karoly HC, Hutchison KE, and Bryan AD. ADHD symptoms impact smoking outcomes and withdrawal in response to Varenicline treatment for smoking cessation. Drug and Alcohol Dependence, 2017; 179:18-24. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28738266
188. Green R, Baker NL, Ferguson PL, Hashemi D, and Gray KM. ADHD symptoms and smoking outcomes in a randomized controlled trial of varenicline for adolescent and young adult tobacco cessation. Drug and Alcohol Dependence, 2023; 244:109798. Available from: https://www.ncbi.nlm.nih.gov/pubmed/36774808
189. Kollins SH, McClernon FJ, and Van Voorhees EE. Monetary incentives promote smoking abstinence in adults with attention deficit hyperactivity disorder (ADHD). Experimental and Clinical Psychopharmacology, 2010; 18(3):221-8. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20545386
190. Reichler H, Baker A, Lewin T, and Carr V. Smoking among in-patients with drug-related problems in an Australian psychiatric hospital. Drug and Alcohol Review, 2001; 20(2):231–7. Available from: http://www.informaworld.com/smpp/content~content=a713659508~db=all~order=page
191. Guydish J, Passalacqua E, Pagano A, Martinez C, Le T, et al. An international systematic review of smoking prevalence in addiction treatment. Addiction, 2016; 111(2):220-30. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26392127
192. Kwon I, Montebello M, and Bittoun R. Tobacco dependence management in a smoke-free inpatient drug and alcohol unit. Australas Psychiatry, 2021; 29(1):14-21. Available from: https://www.ncbi.nlm.nih.gov/pubmed/33301381
193. Rajabi A, Dehghani M, Shojaei A, Farjam M, and Motevalian SA. Association between tobacco smoking and opioid use: A meta-analysis. Addictive Behaviors, 2019; 92:225-35. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30685521
194. Weinberger AH, Pacek LR, Wall MM, Zvolensky MJ, Copeland J, et al. Trends in cannabis use disorder by cigarette smoking status in the United States, 2002-2016. Drug and Alcohol Dependence, 2018; 191:45-51. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30077055
195. Degenhardt L and Hall W. The relationship between tobacco use, substance-use disorders and mental health: results from the National Survey of Mental Health and Well-being. Nicotine & Tobacco Research, 2001; 3(3):225–34. Available from: http://www.informaworld.com/smpp/content~db=all?content=10.1080/14622200110050457
196. Guydish J, Passalacqua E, Tajima B, Chan M, Chun J, et al. Smoking prevalence in addiction treatment: a review. Nicotine & Tobacco Research, 2011; 13(6):401-11. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21464202
197. Degenhardt L and Hall W. Patterns of co-morbidity between alcohol use and other substance use in the Australian population. Drug and Alcohol Review, 2003; 22(1):7–13. Available from: https://pubmed.ncbi.nlm.nih.gov/12745353/
198. Weinberger AH, Funk AP, and Goodwin RD. A review of epidemiologic research on smoking behavior among persons with alcohol and illicit substance use disorders. Preventive Medicine, 2016; 92:148-59. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27196143
199. Hurt RD, Offord KP, Croghan IT, Gomez-Dahl L, Kottke TE, et al. Mortality following inpatient addictions treatment. Role of tobacco use in a community-based cohort. Journal of the American Medical Association, 1996; 275(14):1097-103. Available from: https://www.ncbi.nlm.nih.gov/pubmed/8601929
200. Hobden B, Bryant J, Forshaw K, Oldmeadow C, Evans TJ, et al. Prevalence and characteristics associated with concurrent smoking and alcohol misuse within Australian general practice patients. Aust Health Rev, 2020; 44(1):125-31. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30543764
201. Bien TH and Burge R. Smoking and drinking: a review of the literature. Int J Addict, 1990; 25(12):1429-54. Available from: https://www.ncbi.nlm.nih.gov/pubmed/2094682
202. Hashibe M, Straif K, Tashkin D, Morgenstern H, Greenland S, et al. Epidemiological review of marijuana use and cancer risk. Alcohol, 2005; 35(3):265–75.
203. Ashton CH. Adverse effects of cannabis and cannabinoids. Br J Anaesth, 1999; 83(4):637-49. Available from: https://www.ncbi.nlm.nih.gov/pubmed/10673884
204. Kalant H. Adverse effects of cannabis on health: an update of the literature since 1996. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 2004; 28(849-63).
205. Guydish J, Passalacqua E, Tajima B, and Manser ST. Staff smoking and other barriers to nicotine dependence intervention in addiction treatment settings: a review. J Psychoactive Drugs, 2007; 39(4):423-33. Available from: https://www.ncbi.nlm.nih.gov/pubmed/18303699
206. Fuller BE, Guydish J, Tsoh J, Reid MS, Resnick M, et al. Attitudes toward the integration of smoking cessation treatment into drug abuse clinics. Journal of Substance Abuse Treatment, 2007; 32(1):53-60. Available from: https://www.ncbi.nlm.nih.gov/pubmed/17175398
207. Gentry S, Craig J, Holland R, and Notley C. Smoking cessation for substance misusers: A systematic review of qualitative studies on participant and provider beliefs and perceptions. Drug and Alcohol Dependence, 2017; 180:178-92. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28910690
208. Rothrauff TC and Eby LT. Counselors' knowledge of the adoption of tobacco cessation medications in substance abuse treatment programs. American Journal on Addictions, 2011; 20(1):56-62. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21175921
209. Rothrauff TC, Eby LT, and Public Health S. Substance abuse counselors' implementation of tobacco cessation guidelines. J Psychoactive Drugs, 2011; 43(1):6-13. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21615002
210. Walsh RA, Bowman JA, Tzelepis F, and Lecathelinais C. Smoking cessation interventions in Australian drug treatment agencies: a national survey of attitudes and practices. Drug and Alcohol Review, 2005; 24(3):235-44. Available from: https://www.ncbi.nlm.nih.gov/pubmed/16096127
211. Shu C and Cook BL. Examining the association between substance use disorder treatment and smoking cessation. Addiction, 2015; 110(6):1015-24. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25683883
212. Walsh RA, Bowman JA, Tzelepis F, and Lecathelinais C. Regulation of environmental tobacco smoke by Australian drug treatment agencies. Australian and New Zealand Journal of Public Health, 2005; 29(3):276-8. Available from: https://www.ncbi.nlm.nih.gov/pubmed/15991778
213. Baca C and Yahne C. Smoking cessation during substance abuse treatment: What you need to know. Journal of Substance Abuse Treatment, 2008; 36(2):205–19. Available from: http://www.journalofsubstanceabusetreatment.com/article/S0740-5472(08)00097-4/abstract
214. Cookson C, Strang J, Ratschen E, Sutherland G, Finch E, et al. Smoking and its treatment in addiction services: clients' and staff behaviour and attitudes. BMC Health Services Research, 2014; 14:304. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25017205
215. Toussaint DW, VanDeMark NR, Silverstein M, and Stone E. Exploring factors related to readiness to change tobacco use for clients in substance abuse treatment. Journal of Drug Issues, 2009; 39(2). Available from: https://journals.sagepub.com/doi/abs/10.1177/002204260903900203
216. Stuyt EB. Enforced abstinence from tobacco during in-patient dual-diagnosis treatment improves substance abuse treatment outcomes in smokers. American Journal on Addictions, 2015; 24(3):252-7. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25907814
217. Zawertailo LA, Baliunas D, Ivanova A, and Selby PL. Individualized Treatment for Tobacco Dependence in Addictions Treatment Settings: The Role of Current Depressive Symptoms on Outcomes at 3 and 6 Months. Nicotine & Tobacco Research, 2015; 17(8):937-45. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26180218
218. Winhusen TM, Kropp F, Theobald J, and Lewis DF. Achieving smoking abstinence is associated with decreased cocaine use in cocaine-dependent patients receiving smoking-cessation treatment. Drug and Alcohol Dependence, 2014; 134:391-5. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24128381
219. Winhusen TM, Brigham GS, Kropp F, Lindblad R, Gardin JG, 2nd, et al. A randomized trial of concurrent smoking-cessation and substance use disorder treatment in stimulant-dependent smokers. Journal of Clinical Psychiatry, 2014; 75(4):336-43. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24345356
220. McKelvey K, Thrul J, and Ramo D. Impact of quitting smoking and smoking cessation treatment on substance use outcomes: An updated and narrative review. Addictive Behaviors, 2017; 65:161-70. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27816663
221. Walsh H, McNeill A, Purssell E, and Duaso M. A systematic review and Bayesian meta-analysis of interventions which target or assess co-use of tobacco and cannabis in single- or multi-substance interventions. Addiction, 2020; 115(10):1800-14. Available from: https://www.ncbi.nlm.nih.gov/pubmed/32003088
222. Guillaumier A, Skelton E, Shakeshaft A, Farrell M, Tzelepis F, et al. Effect of increasing the delivery of smoking cessation care in alcohol and other drug treatment centres: a cluster-randomized controlled trial. Addiction, 2020; 115(7):1345-55. Available from: https://www.ncbi.nlm.nih.gov/pubmed/31762105
223. Skelton E, Tzelepis F, Shakeshaft A, Guillaumier A, Wood W, et al. Integrating smoking cessation care into routine service delivery in a medically supervised injecting facility: An acceptability study. Addictive Behaviors, 2018; 84:193-200. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29723802
224. Guillaumier A, Skelton E, Tzelepis F, D'Este C, Paul C, et al. Patterns and predictors of nicotine replacement therapy use among alcohol and other drug clients enrolled in a smoking cessation randomised controlled trial. Addictive Behaviors, 2021; 119:106935. Available from: https://www.ncbi.nlm.nih.gov/pubmed/33848758
225. Martinez C, Guydish J, Le T, Tajima B, and Passalacqua E. Predictors of quit attempts among smokers enrolled in substance abuse treatment. Addictive Behaviors, 2015; 40:1-6. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25218064
226. McPherson S, Orr M, Lederhos C, McDonell M, Leickly E, et al. Decreases in smoking during treatment for methamphetamine-use disorders: preliminary evidence. Behav Pharmacol, 2018; 29(4):370-4. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29035917
227. Thurgood SL, McNeill A, Clark-Carter D, and Brose LS. A Systematic Review of Smoking Cessation Interventions for Adults in Substance Abuse Treatment or Recovery. Nicotine & Tobacco Research, 2016; 18(5):993-1001. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26069036
228. Khara M and Okoli CT. The tobacco-dependence clinic: intensive tobacco-dependence treatment in an addiction services outpatient setting. American Journal on Addictions, 2011; 20(1):45-55. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21175920
229. Zawertailo L, Ivanova A, Ng G, Le Foll B, and Selby P. Safety and Efficacy of Varenicline for Smoking Cessation in Alcohol-Dependent Smokers in Concurrent Treatment for Alcohol Use Disorder: A Pilot, Randomized Placebo-Controlled Trial. J Clin Psychopharmacol, 2020; 40(2):130-6. Available from: https://www.ncbi.nlm.nih.gov/pubmed/32068562
230. Fucito LM, Toll BA, Wu R, Romano DM, Tek E, et al. A preliminary investigation of varenicline for heavy drinking smokers. Psychopharmacology (Berl), 2011; 215(4):655-63. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21221531
231. Hurt RT, Ebbert JO, Croghan IT, Schroeder DR, Hurt RD, et al. Varenicline for tobacco-dependence treatment in alcohol-dependent smokers: A randomized controlled trial. Drug and Alcohol Dependence, 2018; 184:12-7. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29324248
232. O'Malley SS, Zweben A, Fucito LM, Wu R, Piepmeier ME, et al. Effect of Varenicline Combined With Medical Management on Alcohol Use Disorder With Comorbid Cigarette Smoking: A Randomized Clinical Trial. JAMA Psychiatry, 2018; 75(2):129-38. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29261824
233. Ray LA, Green R, Enders C, Leventhal AM, Grodin EN, et al. Efficacy of Combining Varenicline and Naltrexone for Smoking Cessation and Drinking Reduction: A Randomized Clinical Trial. American Journal of Psychiatry, 2021; 178(9):818-28. Available from: https://www.ncbi.nlm.nih.gov/pubmed/34080890
234. Hays JT, Hurt RD, Decker PA, Croghan IT, Offord KP, et al. A randomized, controlled trial of bupropion sustained-release for preventing tobacco relapse in recovering alcoholics. Nicotine & Tobacco Research, 2009; 11(7):859-67. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19483180
235. Guo K, Li J, Li J, Chen N, Li Y, et al. The effects of pharmacological interventions on smoking cessation in people with alcohol dependence: A systematic review and meta-analysis of nine randomized controlled trials. International Journal of Clinical Practice, 2021; 75(11):e14594. Available from: https://www.ncbi.nlm.nih.gov/pubmed/34228852
236. Poling J, Rounsaville B, Gonsai K, Severino K, and Sofuoglu M. The safety and efficacy of varenicline in cocaine using smokers maintained on methadone: a pilot study. American Journal on Addictions, 2010; 19(5):401-8. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20716302
237. Yee A, Hoong MC, Joyce YC, and Loh HS. Smoking Cessation Among Methadone-Maintained Patients: A Meta-Analysis. Substance Use and Misuse, 2018; 53(2):276-85. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28857640
238. Druckrey-Fiskaaen KT, Madebo T, Daltveit JT, Vold JH, Furulund E, et al. Integrated Nicotine Replacement and Behavioral Support to Reduce Smoking in Opioid Agonist Therapy: A Randomized Clinical Trial. JAMA Psychiatry, 2025; 82(4):406-14. Available from: https://www.ncbi.nlm.nih.gov/pubmed/39937506
239. Nguyen N, Bold KW, and McClure EA. Urgent need for treatment addressing co-use of tobacco and cannabis: An updated review and considerations for future interventions. Addictive Behaviors, 2024; 158:108118. Available from: https://www.ncbi.nlm.nih.gov/pubmed/39089194
240. Drummond MB, Astemborski J, Lambert AA, Goldberg S, Stitzer ML, et al. A randomized study of contingency management and spirometric lung age for motivating smoking cessation among injection drug users. BMC Public Health, 2014; 14:761. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25074396
241. Rohsenow DJ, Tidey JW, Martin RA, Colby SM, Sirota AD, et al. Contingent vouchers and motivational interviewing for cigarette smokers in residential substance abuse treatment. Journal of Substance Abuse Treatment, 2015; 55:29-38. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25805668
242. Cooney JL, Cooper S, Grant C, Sevarino K, Krishnan-Sarin S, et al. A Randomized Trial of Contingency Management for Smoking Cessation During Intensive Outpatient Alcohol Treatment. Journal of Substance Abuse Treatment, 2017; 72:89-96. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27542442
243. Aonso-Diego G, Gonzalez-Roz A, Krotter A, Garcia-Perez A, and Secades-Villa R. Contingency management for smoking cessation among individuals with substance use disorders: In-treatment and post-treatment effects. Addictive Behaviors, 2021; 119:106920. Available from: https://www.ncbi.nlm.nih.gov/pubmed/33798921
244. Alessi SM, Petry NM, and Urso J. Contingency management promotes smoking reductions in residential substance abuse patients. Journal of Applied Behavior Analysis, 2008; 41(4):617-22. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19192865
245. Dunn K, Sigmon S, Thomas C, Heil S, and Higgins S. Voucher-based contingent reinforcement of smoking abstinence among methadone-maintained patients: a pilot study. Journal of Applied Behavior Analysis, 2008; 41(4):527–38. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19192857
246. Dunn KE, Sigmon SC, Reimann EF, Badger GJ, Heil SH, et al. A contingency-management intervention to promote initial smoking cessation among opioid-maintained patients. Experimental and Clinical Psychopharmacology, 2010; 18(1):37-50. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20158293
247. Jackson MA, Baker AL, Gould GS, Brown AL, Dunlop AJ, et al. Smoking cessation interventions for pregnant women attending treatment for substance use disorders: A systematic review. Addiction, 2022; 117(4):847-60. Available from: https://www.ncbi.nlm.nih.gov/pubmed/34374145
248. Alessi SM and Petry NM. Smoking reductions and increased self-efficacy in a randomized controlled trial of smoking abstinence-contingent incentives in residential substance abuse treatment patients. Nicotine & Tobacco Research, 2014; 16(11):1436-45. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24935755
249. Rohsenow DJ, Tidey JW, Kahler CW, Martin RA, Colby SM, et al. Intolerance for withdrawal discomfort and motivation predict voucher-based smoking treatment outcomes for smokers with substance use disorders. Addictive Behaviors, 2015; 43:18-24. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25531536
250. Rohsenow DJ, Martin RA, Monti PM, Colby SM, Day AM, et al. Motivational interviewing versus brief advice for cigarette smokers in residential alcohol treatment. Journal of Substance Abuse Treatment, 2014; 46(3):346-55. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24210533
251. Kelly PJ, Baker AL, Townsend CJ, Deane FP, Callister R, et al. Healthy Recovery: A Pilot Study of a Smoking and Other Health Behavior Change Intervention for People Attending Residential Alcohol and Other Substance Dependence Treatment. Journal of Dual Diagnosis, 2019; 15(3):207-16. Available from: https://www.ncbi.nlm.nih.gov/pubmed/31122158
252. Nguyen N, Nguyen C, and Thrul J. Digital health for assessment and intervention targeting tobacco and cannabis co-use. Curr Addict Rep, 2020; 7(3):268-79. Available from: https://www.ncbi.nlm.nih.gov/pubmed/33643768
253. McClure JB and Lapham G. Tobacco quitline engagement and outcomes among primary care patients reporting use of tobacco or dual tobacco and cannabis: An observational study. Substance Abuse, 2021; 42(4):417-22. Available from: https://www.ncbi.nlm.nih.gov/pubmed/33270541
254. Bowman J and Walsh R. Smoking intervention within alcohol and other drug treatment services: a selective review with suggestions for practical management. Drug and Alcohol Review, 2003; 22(1):73–82. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1080/0959523021000059857
255. Guydish J, Ziedonis D, Tajima B, Seward G, Passalacqua E, et al. Addressing Tobacco Through Organizational Change (ATTOC) in residential addiction treatment settings. Drug and Alcohol Dependence, 2012; 121(1-2):30-7. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21906892
256. Knudsen HK. Implementation of smoking cessation treatment in substance use disorder treatment settings: a review. American Journal of Drug and Alcohol Abuse, 2017; 43(2):215-25. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27314884
257. Allsop S, Carter O, and Lenton S. Enhancing clinical research with alcohol, tobacco and cannabis problems and dependence. Drug and Alcohol Review, 2010; 29(5):483-90. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20887571
258. Kearns NT, Carl E, Stein AT, Vujanovic AA, Zvolensky MJ, et al. Posttraumatic stress disorder and cigarette smoking: A systematic review. Depress Anxiety, 2018; 35(11):1056-72. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30192425
259. Pericot-Valverde I, Elliott RJ, Miller ME, Tidey JW, and Gaalema DE. Posttraumatic stress disorder and tobacco use: A systematic review and meta-analysis. Addictive Behaviors, 2018; 84:238-47. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29753221
260. van den Berk-Clark C, Secrest S, Walls J, Hallberg E, Lustman PJ, et al. Association between posttraumatic stress disorder and lack of exercise, poor diet, obesity, and co-occuring smoking: A systematic review and meta-analysis. Health Psychology, 2018; 37(5):407-16. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29698016
261. Shevorykin A, Hyland BM, Robles D, Ji M, Vantucci D, et al. Tobacco use, trauma exposure and PTSD: a systematic review. Health Psychol Rev, 2024; 18(4):649-80. Available from: https://www.ncbi.nlm.nih.gov/pubmed/38711288
262. Mould DR and Meibohm B. Drug Development of Therapeutic Monoclonal Antibodies. BioDrugs, 2016; 30(4):275-93. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27342605
263. Flanagan JC, Hakes JK, McClure EA, Snead AL, and Back SE. Effects of intimate partner violence, PTSD, and alcohol use on cigarette smoking in a nationally representative sample. American Journal on Addictions, 2016; 25(4):283-90. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27196699
264. Hammett PJ, Japuntich SJ, Sherman SE, Rogers ES, Danan ER, et al. Proactive tobacco treatment for veterans with posttraumatic stress disorder. Psychol Trauma, 2021; 13(1):114-22. Available from: https://www.ncbi.nlm.nih.gov/pubmed/32614201
265. Hawes MR, Roth KB, and Cabassa LJ. Systematic Review of Psychosocial Smoking Cessation Interventions for People with Serious Mental Illness. Journal of Dual Diagnosis, 2021; 17(3):216-35. Available from: https://www.ncbi.nlm.nih.gov/pubmed/34281493
266. Kertes J, Stein Reisner O, Grunhaus L, Nezry R, Alcalay T, et al. Comparison of Smoking Cessation Program Registration, Participation, Smoking Cessation Medication Utilization, and Abstinence Rates Between Smokers With and Without Schizophrenia, Schizo-affective Disorder, or Bipolar Disorder. Nicotine & Tobacco Research, 2022; 24(5):670-8. Available from: https://www.ncbi.nlm.nih.gov/pubmed/34626108
267. Pearsall R, Smith DJ, and Geddes JR. Pharmacological and behavioural interventions to promote smoking cessation in adults with schizophrenia and bipolar disorders: a systematic review and meta-analysis of randomised trials. BMJ Open, 2019; 9(11):e027389. Available from: https://www.ncbi.nlm.nih.gov/pubmed/31784428
268. Gilbody S, Peckham E, Bailey D, Arundel C, Heron P, et al. Smoking cessation in severe mental illness: combined long-term quit rates from the UK SCIMITAR trials programme. The British Journal of Psychiatry, 2021; 218(2):95-7. Available from: https://www.ncbi.nlm.nih.gov/pubmed/31685048
269. Peckham E, Arundel C, Bailey D, Crosland S, Fairhurst C, et al. A bespoke smoking cessation service compared with treatment as usual for people with severe mental ill health: the SCIMITAR+ RCT. Health Technology Assessment, 2019; 23(50):1-116. Available from: https://www.ncbi.nlm.nih.gov/pubmed/31549622
270. Spanakis P, Peckham E, Young B, Heron P, Bailey D, et al. A systematic review of behavioural smoking cessation interventions for people with severe mental ill health-what works? Addiction, 2022; 117(6):1526-42. Available from: https://www.ncbi.nlm.nih.gov/pubmed/34697848
271. Baker AL, Richmond R, Kay-Lambkin FJ, Filia SL, Castle D, et al. Randomised controlled trial of a healthy lifestyle intervention among smokers with psychotic disorders: Outcomes to 36 months. Australian and New Zealand Journal of Psychiatry, 2018; 52(3):239-52. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28610482
272. Sharma R, Alla K, Pfeffer D, Meurk C, Ford P, et al. An appraisal of practice guidelines for smoking cessation in people with severe mental illness. Australian and New Zealand Journal of Psychiatry, 2017; 51(11):1106-20. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28859486
273. Jackson JG, Diaz FJ, Lopez L, and de Leon J. A combined analysis of worldwide studies demonstrates an association between bipolar disorder and tobacco smoking behaviors in adults. Bipolar Disorders, 2015; 17(6):575-97. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26238269
274. George TP, Wu BS, and Weinberger AH. A Review of Smoking Cessation in Bipolar Disorder: Implications for Future Research. Journal of Dual Diagnosis, 2012; 8(2):126-30. Available from: https://www.ncbi.nlm.nih.gov/pubmed/22737046
275. Grunze A, Mosolov S, Grunze H, and Born C. The detrimental effects of smoking on the course and outcome in adults with bipolar disorder-A narrative review. Front Psychiatry, 2022; 13:1114432. Available from: https://www.ncbi.nlm.nih.gov/pubmed/36699491
276. Slyepchenko A, Brunoni AR, McIntyre RS, Quevedo J, and Carvalho AF. The Adverse Effects of Smoking on Health Outcomes in Bipolar Disorder: A Review and Synthesis of Biological Mechanisms. Curr Mol Med, 2016; 16(2):187-205. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26812916
277. Thomson D, Berk M, Dodd S, Rapado-Castro M, Quirk SE, et al. Tobacco use in bipolar disorder. Clinical Psychopharmacology and Neuroscience, 2015; 13(1):1-11. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25912533
278. Weinberger AH, Vessicchio JC, Sacco KA, Creeden CL, Chengappa KN, et al. A preliminary study of sustained-release bupropion for smoking cessation in bipolar disorder. J Clin Psychopharmacol, 2008; 28(5):584-7. Available from: https://www.ncbi.nlm.nih.gov/pubmed/18794666
279. Wu BS, Weinberger AH, Mancuso E, Wing VC, Haji-Khamneh B, et al. A Preliminary Feasibility Study of Varenicline for Smoking Cessation in Bipolar Disorder. Journal of Dual Diagnosis, 2012; 8(2):131-2. Available from: https://www.ncbi.nlm.nih.gov/pubmed/22962546
280. Evins AE, Cather C, Pratt SA, Pachas GN, Hoeppner SS, et al. Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. Journal of the American Medical Association, 2014; 311(2):145-54. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24399553
281. Chengappa KN, Perkins KA, Brar JS, Schlicht PJ, Turkin SR, et al. Varenicline for smoking cessation in bipolar disorder: a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry, 2014; 75(7):765-72. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25006684
282. Heffner JL, Evins AE, Russ C, Lawrence D, Ayers CR, et al. Safety and efficacy of first-line smoking cessation pharmacotherapies in bipolar disorders: Subgroup analysis of a randomized clinical trial. J Affect Disord, 2019; 256:267-77. Available from: https://www.ncbi.nlm.nih.gov/pubmed/31195244
283. Heffner JL, Mull KE, Watson NL, McClure JB, and Bricker JB. Smokers with bipolar disorder, other affective disorders, and no mental health conditions: Comparison of baseline characteristics and success at quitting in a large 12-month behavioral intervention randomized trial. Drug and Alcohol Dependence, 2018; 193:35-41. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30340143
284. Heffner JL, Kelly MM, Waxmonsky J, Mattocks K, Serfozo E, et al. Pilot Randomized Controlled Trial of Web-Delivered Acceptance and Commitment Therapy Versus Smokefree.gov for Smokers With Bipolar Disorder. Nicotine & Tobacco Research, 2020; 22(9):1543-52. Available from: https://www.ncbi.nlm.nih.gov/pubmed/31883336
285. McGrath JJ and Susser ES. New directions in the epidemiology of schizophrenia. Medical Journal of Australia, 2009; 190(S4):S7-9. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19220176
286. de Leon J and Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res, 2005; 76(2-3):135-57. Available from: https://www.ncbi.nlm.nih.gov/pubmed/15949648
287. Williams J and Ziedonis D. Addressing tobacco among individuals with a mental illness or an addiction. Addictive Behaviors, 2004; 29(6):1067–83. Available from: https://pubmed.ncbi.nlm.nih.gov/15236808/
288. Williams JM, Gandhi KK, Lu SE, Kumar S, Steinberg ML, et al. Shorter interpuff interval is associated with higher nicotine intake in smokers with schizophrenia. Drug and Alcohol Dependence, 2011; 118(2-3):313-9. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21596491
289. Callaghan RC, Veldhuizen S, Jeysingh T, Orlan C, Graham C, et al. Patterns of tobacco-related mortality among individuals diagnosed with schizophrenia, bipolar disorder, or depression. Journal of Psychiatric Research, 2014; 48(1):102-10. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24139811
290. Cocks N, Brophy L, Segan C, Stratford A, Jones S, et al. Psychosocial Factors Affecting Smoking Cessation Among People Living With Schizophrenia: A Lived Experience Lens. Front Psychiatry, 2019; 10:565. Available from: https://www.ncbi.nlm.nih.gov/pubmed/31474884
291. Zeng LN, Zong QQ, Zhang L, Feng Y, Ng CH, et al. Worldwide prevalence of smoking cessation in schizophrenia patients: A meta-analysis of comparative and observational studies. Asian J Psychiatr, 2020; 54:102190. Available from: https://www.ncbi.nlm.nih.gov/pubmed/32622029
292. Williams JM and Foulds J. Successful tobacco dependence treatment in schizophrenia. American Journal of Psychiatry, 2007; 164(2):222-7; quiz 373. Available from: https://www.ncbi.nlm.nih.gov/pubmed/17267783
293. Kelly DL, Raley HG, Lo S, Wright K, Liu F, et al. Perception of smoking risks and motivation to quit among nontreatment-seeking smokers with and without schizophrenia. Schizophrenia Bulletin, 2012; 38(3):543-51. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21041835
294. Williams JM and Ziedonis DM. Snuffing out tobacco dependence. Ten reasons behavioral health providers need to be involved. Behav Healthc, 2006; 26(5):27-31. Available from: https://www.ncbi.nlm.nih.gov/pubmed/16736916
295. Tsoi DT, Porwal M, and Webster AC. Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database of Systematic Reviews, 2013; 2013(2):CD007253. Available from: https://www.ncbi.nlm.nih.gov/pubmed/23450574
296. Oluwoye O, Monroe-DeVita M, Burduli E, Chwastiak L, McPherson S, et al. Impact of tobacco, alcohol and cannabis use on treatment outcomes among patients experiencing first episode psychosis: Data from the national RAISE-ETP study. Early Interv Psychiatry, 2019; 13(1):142-6. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29356438
297. Clark V, Conrad AM, Lewin TJ, Baker AL, Halpin SA, et al. Addiction Vulnerability: Exploring Relationships Among Cigarette Smoking, Substance Misuse, and Early Psychosis. Journal of Dual Diagnosis, 2018; 14(2):78-88. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29261427
298. Curtis J, Zhang C, McGuigan B, Pavel-Wood E, Morell R, et al. y-QUIT: Smoking Prevalence, Engagement, and Effectiveness of an Individualized Smoking Cessation Intervention in Youth With Severe Mental Illness. Front Psychiatry, 2018; 9:683. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30618864
299. Baker A, Richmond R, Lewin TJ, and Kay-Lambkin F. Cigarette smoking and psychosis: naturalistic follow up 4 years after an intervention trial. Australian and New Zealand Journal of Psychiatry, 2010; 44(4):342-50. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20307166
300. Miyauchi M, Kishida I, Suda A, Shiraishi Y, Fujibayashi M, et al. Long term effects of smoking cessation in hospitalized schizophrenia patients. BMC Psychiatry, 2017; 17(1):87. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28270120
301. Evins AE and Cather C. Effective Cessation Strategies for Smokers with Schizophrenia. Int Rev Neurobiol, 2015; 124:133-47. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26472528
302. US Food and Drug Administration (FDA). Joint Meeting of the Psychopharmacologic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee. 2016. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM520103.pdf
303. Jeon DW, Shim JC, Kong BG, Moon JJ, Seo YS, et al. Adjunctive varenicline treatment for smoking reduction in patients with schizophrenia: A randomized double-blind placebo-controlled trial. Schizophr Res, 2016; 176(2-3):206-11. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27543252
304. Smith RC, Amiaz R, Si TM, Maayan L, Jin H, et al. Varenicline Effects on Smoking, Cognition, and Psychiatric Symptoms in Schizophrenia: A Double-Blind Randomized Trial. PLoS One, 2016; 11(1):e0143490. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26730716
305. Shawen AE and Drayton SJ. Review of pharmacotherapy for smoking cessation in patients with schizophrenia. Ment Health Clin, 2018; 8(2):78-85. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29955550
306. Wu Q, Gilbody S, Peckham E, Brabyn S, and Parrott S. Varenicline for smoking cessation and reduction in people with severe mental illnesses: systematic review and meta-analysis. Addiction, 2016; 111(9):1554-67. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27043328
307. Ahmed S, Virani S, Kotapati VP, Bachu R, Adnan M, et al. Efficacy and Safety of Varenicline for Smoking Cessation in Schizophrenia: A Meta-Analysis. Front Psychiatry, 2018; 9:428. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30283363
308. Siskind DJ, Wu BT, Wong TT, Firth J, and Kisely S. Pharmacological interventions for smoking cessation among people with schizophrenia spectrum disorders: a systematic review, meta-analysis, and network meta-analysis. Lancet Psychiatry, 2020; 7(9):762-74. Available from: https://www.ncbi.nlm.nih.gov/pubmed/32828166
309. Cather C, Pachas GN, Cieslak KM, and Evins AE. Achieving Smoking Cessation in Individuals with Schizophrenia: Special Considerations. CNS Drugs, 2017; 31(6):471-81. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28550660
310. Kozak K and George TP. Pharmacotherapy for smoking cessation in schizophrenia: a systematic review. Expert Opin Pharmacother, 2020; 21(5):581-90. Available from: https://www.ncbi.nlm.nih.gov/pubmed/32011186
311. Pinho S, Rocha V, and Vieira-Coelho MA. Effectiveness of multimodal interventions focused on smoking cessation in patients with schizophrenia: A systematic review. Schizophr Res, 2021; 231:145-53. Available from: https://www.ncbi.nlm.nih.gov/pubmed/33857662
312. Rajalu BM, Jayarajan D, Muliyala KP, Sharma P, Gandhi S, et al. Non-pharmacological interventions for smoking in persons with schizophrenia spectrum disorders - A systematic review. Asian J Psychiatr, 2021; 56:102530. Available from: https://www.ncbi.nlm.nih.gov/pubmed/33465747
313. Ding JB and Hu K. Cigarette Smoking and Schizophrenia: Etiology, Clinical, Pharmacological, and Treatment Implications. Schizophr Res Treatment, 2021; 2021:7698030. Available from: https://www.ncbi.nlm.nih.gov/pubmed/34938579
314. Scott JG, Matuschka L, Niemela S, Miettunen J, Emmerson B, et al. Evidence of a Causal Relationship Between Smoking Tobacco and Schizophrenia Spectrum Disorders. Front Psychiatry, 2018; 9:607. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30515111
315. Skelton E, Tzelepis F, Shakeshaft A, Guillaumier A, Dunlop A, et al. Smoking cessation care provision in Australian alcohol and other drug treatment services: A cross-sectional survey of staff self-reported practices. Journal of Substance Abuse Treatment, 2017; 77:101-6. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28476261
316. Sharma R, Meurk C, Bell S, Ford P, and Gartner C. Australian mental health care practitioners' practices and attitudes for encouraging smoking cessation and tobacco harm reduction in smokers with severe mental illness. International Journal of Mental Health Nursing, 2018; 27(1):247-57. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28160384
317. Abrantes A, Strong D, Lloyd-Richardson E, Niaura R, Kahler C, et al. Regular exercise as a protective factor in relapse following smoking cessation treatment. American Journal on Addictions, 2009; 18(1):100–1. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19219672
318. Ratschen E, Britton J, Doody GA, Leonardi-Bee J, and McNeill A. Tobacco dependence, treatment and smoke-free policies: a survey of mental health professionals' knowledge and attitudes. General Hospital Psychiatry, 2009; 31(6):576-82. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19892217
319. Skelton E, Tzelepis F, Shakeshaft A, Guillaumier A, Dunlop A, et al. Addressing tobacco in Australian alcohol and other drug treatment settings: a cross-sectional survey of staff attitudes and perceived barriers. Substance Abuse Treatment, Prevention, and Policy, 2017; 12(1):20. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28464898
320. Wye P, Bowman J, Wiggers J, Baker A, Carr V, et al. Providing nicotine dependence treatment to psychiatric inpatients: the views of Australian nurse managers. J Psychiatr Ment Health Nurs, 2010; 17(4):319-27. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20529182
321. Pagano A, Tajima B, and Guydish J. Barriers and Facilitators to Tobacco Cessation in a Nationwide Sample of Addiction Treatment Programs. Journal of Substance Abuse Treatment, 2016; 67:22-9. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27296658
322. Sheals K, Tombor I, McNeill A, and Shahab L. A mixed-method systematic review and meta-analysis of mental health professionals' attitudes toward smoking and smoking cessation among people with mental illnesses. Addiction, 2016; 111(9):1536-53. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27003925
323. Minian N, Noormohamed A, Lingam M, Zawertailo L, Le Foll B, et al. Integrating a brief alcohol intervention with tobacco addiction treatment in primary care: qualitative study of health care practitioner perceptions. Addiction Science & Clinical Practice, 2021; 16(1):17. Available from: https://www.ncbi.nlm.nih.gov/pubmed/33726843
324. Malone V, Harrison R, and Daker-White G. Mental health service user and staff perspectives on tobacco addiction and smoking cessation: A meta-synthesis of published qualitative studies. J Psychiatr Ment Health Nurs, 2018; 25(4):270-82. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29498459
325. Short B, Giles L, Karageorge A, and Bauer L. Exploring and reorienting psychiatrists' attitudes regarding smoking cessation and its potential to improve mental health outcomes: a pilot study. Australas Psychiatry, 2021; 29(6):663-7. Available from: https://www.ncbi.nlm.nih.gov/pubmed/34488489
326. Huddlestone L, Shoesmith E, Pervin J, Lorencatto F, Watson J, et al. A Systematic Review of Mental Health Professionals, Patients, and Carers' Perceived Barriers and Enablers to Supporting Smoking Cessation in Mental Health Settings. Nicotine & Tobacco Research, 2022; 24(7):945-54. Available from: https://www.ncbi.nlm.nih.gov/pubmed/35018458
327. Johnson JL, Malchy LA, Ratner PA, Hossain S, Procyshyn RM, et al. Community mental healthcare providers' attitudes and practices related to smoking cessation interventions for people living with severe mental illness. Patient Education and Counseling, 2009; 77(2):289-95. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19398293
328. Schwindt RG, McNelis AM, and Sharp D. Evaluation of a theory-based education program to motivate nursing students to intervene with their seriously mentally ill clients who use tobacco. Archives of Psychiatric Nursing, 2014; 28(4):277-83. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25017562
329. Williams JM, Stroup TS, Brunette MF, and Raney LE. Tobacco use and mental illness: a wake-up call for psychiatrists. Psychiatric Services, 2014; 65(12):1406-8. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25270381
330. Cerimele JM, Halperin AC, and Saxon AJ. Tobacco use treatment in primary care patients with psychiatric illness. Journal of the American Board of Family Medicine, 2014; 27(3):399-410. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24808119
331. Mitchell AJ, Vancampfort D, De Hert M, and Stubbs B. Do people with mental illness receive adequate smoking cessation advice? A systematic review and meta-analysis. General Hospital Psychiatry, 2015; 37(1):14-23. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25510845
332. Shi Y. Smoking cessation among people seeking mental health treatment. Psychiatric Services, 2014; 65(7):957-60. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26037007
333. Rogers E and Sherman S. Tobacco use screening and treatment by outpatient psychiatrists before and after release of the American Psychiatric Association treatment guidelines for nicotine dependence. American Journal of Public Health, 2014; 104(1):90-5. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24228666
334. Taylor GMJ, Itani T, Thomas KH, Rai D, Jones T, et al. Prescribing Prevalence, Effectiveness, and Mental Health Safety of Smoking Cessation Medicines in Patients With Mental Disorders. Nicotine & Tobacco Research, 2020; 22(1):48-57. Available from: https://www.ncbi.nlm.nih.gov/pubmed/31289809
335. Metse AP, Wiggers J, Wye P, and Bowman JA. Patient receipt of smoking cessation care in four Australian acute psychiatric facilities. International Journal of Mental Health Nursing, 2018; 27(5):1556-63. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29573164
336. [No authors listed]. An official position statement of the Association of Women’s Health, Obstetric & Neonatal Nursing. Journal of Obstetric, Gynecologic, and Neonatal Nursing, 2010; 39(5):611–3. Available from: http://onlinelibrary.wiley.com/doi/10.1111/j.1552-6909.2010.01178.x/full
337. McFall M, Saxon AJ, Malte CA, Chow B, Bailey S, et al. Integrating tobacco cessation into mental health care for posttraumatic stress disorder: a randomized controlled trial. Journal of the American Medical Association, 2010; 304(22):2485-93. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21139110
338. Quit Victoria. Mental health settings. Available from: https://www.quit.org.au/resources/mental-health/
339. Adams CE, Baillie LE, and Copeland AL. The Smoking-Related Weight and Eating Episodes Test (SWEET): development and preliminary validation. Nicotine & Tobacco Research, 2011; 13(11):1123-31. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21849410
340. Ashton M. Policy within mental health services- pro-actively addressing tobacco. Presented at the The Mental Health Service Conference. Sydney. 2005.
341. Skelton E, Tzelepis F, Shakeshaft A, Guillaumier A, Wood W, et al. Integrating Smoking Cessation Care into a Medically Supervised Injecting Facility Using an Organizational Change Intervention: A Qualitative Study of Staff and Client Views. International Journal of Environmental Research and Public Health, 2019; 16(11). Available from: https://www.ncbi.nlm.nih.gov/pubmed/31185619
342. Wye P, Bowman J, Wiggers J, Baker A, Carr V, et al. An audit of the prevalence of recorded nicotine dependence treatment in an Australian psychiatric hospital. Australian and New Zealand Journal of Public Health, 2010; 34(3):298-303. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20618273
343. Wye PM, Bowman JA, Wiggers JH, Baker A, Knight J, et al. Smoking restrictions and treatment for smoking: policies and procedures in psychiatric inpatient units in Australia. Psychiatric Services, 2009; 60(1):100-7. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19114578
344. Schnoll RA, Leone FT, Quinn MH, Stevens N, Flitter A, et al. A randomized clinical trial testing two implementation strategies to promote the treatment of tobacco dependence in community mental healthcare. Drug and Alcohol Dependence, 2023; 247:109873. Available from: https://www.ncbi.nlm.nih.gov/pubmed/37084508
345. Plever S, Kisely S, Bonevski B, McCarthy I, Anzolin M, et al. Increases in delivery of a brief smoking cessation intervention following implementation of a system change intervention in community psychiatry settings. Australian and New Zealand Journal of Psychiatry, 2025; 59(7):602-11. Available from: https://www.ncbi.nlm.nih.gov/pubmed/40396288
346. Plever S, Kisely S, Bonevski B, McCarthy I, Emmerson B, et al. Can improvement in delivery of smoking cessation care be sustained in psychiatry inpatient settings through a system change intervention? An analysis of statewide administrative health data. Australian and New Zealand Journal of Psychiatry, 2023; 57(10):1375-83. Available from: https://www.ncbi.nlm.nih.gov/pubmed/37038343
347. Abrams DB, Graham AL, Levy DT, Mabry PL, and Orleans CT. Boosting population quits through evidence-based cessation treatment and policy. American Journal of Preventive Medicine, 2010; 38(3 Suppl):S351-63. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20176308
348. Shmueli D, Fletcher L, Hall S, Hall S, and Prochaska J. Changes in psychiatric patients' thoughts about quitting smoking during a smoke-free hospitalization. Nicotine & Tobacco Research, 2008; 10(5):875–81. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18569762
349. Keizer I, Descloux V, and Eytan A. Variations in smoking after admission to psychiatric inpatient units and impact of a partial smoking ban on smoking and on smoking-related perceptions. Int J Soc Psychiatry, 2009; 55(2):109-23. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19240201
350. Stockings EA, Bowman JA, Prochaska JJ, Baker AL, Clancy R, et al. The impact of a smoke-free psychiatric hospitalization on patient smoking outcomes: a systematic review. Australian and New Zealand Journal of Psychiatry, 2014; 48(7):617-33. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24819934
351. Leyro TM, Hall SM, Hickman N, Kim R, Hall SE, et al. Clinical management of tobacco dependence in inpatient psychiatry: provider practices and patient utilization. Psychiatric Services, 2013; 64(11):1161-5. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24185538
352. Spiers A, Chin CS, Ng KY, Taran M, Thornton P, et al. Violence and nicotine replacement therapy in a high dependency mental health unit. Australas Psychiatry, 2025; 33(4):640-4. Available from: https://www.ncbi.nlm.nih.gov/pubmed/40010323
353. Sourry RJ, Hyslop F, Butler TG, and Richmond RL. Impact of smoking bans and other smoking cessation interventions in prisons, mental health and substance use treatment settings: A systematic review of the evidence. Drug and Alcohol Review, 2022; 41(7):1528-42. Available from: https://www.ncbi.nlm.nih.gov/pubmed/36097413
354. Prochaska JJ, Fletcher L, Hall SE, and Hall SM. Return to smoking following a smoke-free psychiatric hospitalization. American Journal on Addictions, 2006; 15(1):15-22. Available from: https://www.ncbi.nlm.nih.gov/pubmed/16449089
355. Vorspan F, Bloch V, Guillem E, Dupuy G, Pirnay S, et al. Smoking ban in a psychiatry department: are nonsmoking employees less exposed to environmental tobacco smoke? European Psychiatry, 2009; 24(8):529-32. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19540729
356. Stockings EA, Bowman JA, Bartlem KM, McElwaine KM, Baker AL, et al. Implementation of a smoke-free policy in an inpatient psychiatric facility: Patient-reported adherence, support, and receipt of nicotine-dependence treatment. International Journal of Mental Health Nursing, 2015; 24(4):342-9. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25970237
357. Filia SL, Gurvich CT, Horvat A, Shelton CL, Katona LJ, et al. Inpatient views and experiences before and after implementing a totally smoke-free policy in the acute psychiatry hospital setting. International Journal of Mental Health Nursing, 2015; 24(4):350-9. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26189488
358. Magor-Blatch LE and Rugendyke AR. Going smoke-free: attitudes of mental health professionals to policy change. J Psychiatr Ment Health Nurs, 2016; 23(5):290-302. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27278902
359. Dean TD, Cross W, and Munro I. An Exploration of the Perspectives of Associate Nurse Unit Managers Regarding the Implementation of Smoke-free Policies in Adult Mental Health Inpatient Units. Issues Ment Health Nurs, 2018; 39(4):328-36. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29436879
360. de Oliveira RM and Furegato AR. The decreasing number of cigarettes during psychiatric hospitalization: intervention or punishment? Revista Brasileira de Enfermagem, 2015; 68(1):69-76, -83. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25946498
361. Chapman S. A complete smoking ban in psychiatric hospitals is ethically wrong. British Medical Journal, 2015; 351:h6288. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26607749
362. Arnott D, Wessely S, and Fitzpatrick M. Should psychiatric hospitals completely ban smoking? British Medical Journal, 2015; 351:h5654. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26536887